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ABSTRACT Boron neutron capture therapy (BNCT) is a binary form of cancer treatment wherein 1°B nuclei, when irradiated with thermal neutrons, produce high linear energy transfer particles. These particles, because of their size and energy, are confined to a radius of approximately 9-10 µm, which is comparable to the dimensions of a single cell. The success of BNCT depends upon the development of non-toxic compounds that have the ability to accumulate in tumor cells selectively in the presence of normal cells and are able to achieve concentration levels in the range of 20-35 µg of 1°B per gram of tumor. Potential BNCT agents reported in literature include boron-containing amino acids, carbohydrates, nucleic acids, nucleosides, antibodies, and other biomolecules. This dissertation describes the strategies and methods employed in the synthesis of boronated analogues of a cylcooxygenase-2 (COX-2) enzyme inhibitor, celecoxib, and boronated unnatural cyclic amino acids as potential BNCT agents. Monosubstituted boron-containing analogues of celecoxib were synthesized. Significant progress was made towards the synthesis of the disubstituted analogues. A radiolabeled analogue of celecoxib for potential use as a Single photon emission computed tomography (SPECT) agent for imaging tumors was also achieved. The syntheses of five-membered and seven-membered boronated unnatural cyclic amino acids were accomplished. A synthetic strategy was proposed for a water soluble, carborane-containing cascade polyol derivative of the five-membered amino vii 
acid. The progress made towards the synthesis of this water-soluble derivative is also described. Previous studies reported in literature concerning COX-2 inhibitors and cyclic amino acids provide a good basis for their choice as potential BNCT agents. It is believed that the boronated analogues of celecoxib, and· the cyclic amino acids, off er good promise for potential use in cancer treatment. A study of the biodistribution and evaluation of some of these compounds is currently underway. viii 
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Chapter l Introduction 
§ 1.1 BORON NEUTRON CAPTURE THERAPY Boron neutron capture therapy (BNCT) is a binary form of cancer treatment . whereby 1°B nuclei, when irradiated with thermal neutrons, generate high linear energy transfer (LET) particles. These particles, because of their size and energy, are restricted to a radius of approximately 9-10 µm, comparable to the dimensions of a single cell. The lethal radiant energy of these particles thus does not affect adjacent normal cells. 1 '2 The boron neutron capture reaction obtained with thermal neutrons is shown below. 10 1 [ 1 1  ] B + n ___,. B ---. 
5 0 5 
4 7 He + Li 
2 3 
+ y 0.48MeV + 2.31MeV Many different classes of boron compounds have been synthesized as potential BNCT agents. These include boron-containing amino acids, 3-5 hydantoins,6•7 carbohydrates,8•9 porphyrins, 10- 1 2  nucleosides, 1 3• 1 4  nucleotides, 1 3• 14 nucleic acids, 1 3' 14 liposomes, 1 5- 17 lipoproteins, 1 8 antibodies, 1 9•20 immunoconjugates, 1 9•20 and other biomolecules. This dissertation deals with the synthesis of boron-containing analogues of the specific cyclooxygenase-2 (COX-2) enzyme inhibitor, celecoxib (commonly known as celebrex), and the synthesis of boron-containing unnatural cyclic amino acids as potential BNCT agents for cancer treatment. The former set of compounds 1 
has also been used in this research as precursors in the synthesis of radiolabeled tumor imaging agents using Single photon emission computed tomography (SPECT). This technique will be introduced in Section 1 .2. 
§ 1.1.1 Celecoxib and Colon Cancer Colon cancer is one of the leading causes of cancer deaths in western countries, including the United States. 21 High levels of prostaglandins have been demonstrated in various cancers including colon cancer. 22 •23 Several epidemiological investigations point towards an inverse relationship between the intake of nonsteroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer risk.24-34 The mechanism by which NSAIDs inhibit colon carcinogenesis is not clearly understood but could possibly involve inhibition of prostaglanclin production by blockage of the cyclooxygenase (COX- 1 and COX-2) enzymes.35 It has been suggested that multiple mechanisms may be involved in the action of NSAIDs, many of which may be prostaglandin independent.34 These mechanisms are outlined in Section 2.2.7. Typical NSAIDs inhibit both COX- 1 and COX-2 in a non-selective manner. Overexpression of the COX-2 enzyme has been observed in colon carcinomas; therefore, specific inhibitors of COX-2 activity could potentially serve as chemopreventive agents against colon carcinogenesis.35•36 Non-selective inhibitors of COX- I and COX-2 have been shown to effectively inhibit tumorigenesis by 70-98% and eliminate established tumors by 75-98%.34 Sulindac, a non-selective NSAID, has been shown to reduce tumor number by as much as 99% in ApcMint+ mice. 37 It is not 2 
clear if selective COX-2 inhibitors have additional chemopreventive advantages as 
compared to the non-selective inhibitors although serious problems of 
gastrointestinal ulceration can result from chronic non-selective NSAID use. 
Celecoxib, a potent and specific COX-2 inhibitor, was found to inhibit the 
occurrence and multiplicity of colon tumors by 93 to 97% and curb the overall tumor 
burden by more than 87%.38 Celecoxib also demonstrated potent antitumor activity 
in vivo,39 signifying a novel application and potential use of this  anti-inflammatory 
drug in the treatment of human cancer. For this reason, we have focused our efforts 
on analogues of celecoxib as boron carriers. 
§ 1.1.2 Unnatural Cyclic Amino Acids It is believed that amino acids are preferentially taken up by growing tumor 
cells. It is for this reason that boron-containing amino acid derivatives have been 
studied as potential BNCT agents. The only drug currently used in BNCT clinical 
trials in the United States is a boronated phenylalanine (BPA).40 Positron emission 
tomography (PET) investigations carried out at the University of Tennessee on 
BNCT patients using both fluorine- 18  labeled BP A and carbon-1 1  labeled 1-
aminocyclobutanecarboxylic acid (ACBC) revealed that cyclic amino acids localize 
in glioblastoma multiforme (malignant brain tumor) more avidly than BP A.41 For 
this reason, we have focused our efforts on cyclic amino acids as boron carriers. 3 
§ 1.2 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SPECT involves the detection of gamma rays emitted singly from radionuclides and the determination of relative or absolute regional concentrations of these radionuclides as a function of time within small regions of the body.42 Some of the radionuclides thatemit gamma rays include technetium-99m, thallium 201, iodine-123, indium-111, and gallium-67. SPECT data involve the accumulation of projection data consisting of a number of line integrals measured from different views around the patient. These data are then reconstructed using mathematical equations. In principle, a chemically stable radiolabeled compound could be used for tumor imaging via SPECT and thus provide valuable information about a particular disease. A number of radiopharmaceuticals have been synthesized as potential SPECT agents and used as diagnostic tools in a variety of diseases such as in �alignant brain tumors,43 in Alzheimer's disease,44 in non-small cell lung cancer,45 in schizophrenic patients,46 and in the study of anti-depressant effects in major depression.47 To explore the possibility of SPECT as a diagnostic tool in colon cancer, we have focused our efforts on the synthesis of an iodine-123 labeled analogue of potent cyclooxygenase-2 (COX-2) enzyme inhibitor, celecoxib. High levels of the COX-2 enzyme have been found in colon tumors, hence a selective COX-2 inhibitor like celecoxib could serve as an ideal imaging agent for colon tumors. 
4 
Chapter 2 Literature Review 
§ 2.1 BORON NEUTRON CAPTURE THERAPY This section describes the origin, background, and current status of. developments in boron neutron capture therapy (BNCT). BNCT was introduced as a new technique to overcome some of the limitations of the current therapies of cancer, as is described in the sections to follow. 
§ 2.1.1 Contemporary Therapies of Cancer The incentive for developing new methods for treatment of cancer has arisen from the drawbacks of existing therapies.2 In the case of most cancers involving solid tumors, surgical removal of the malignant tumor is the preferred method of treatment. However, there is always doubt as to whether all the malignant cells have been removed. Residual malignant cells could become the foci for tumor recurrences either at the original site of the tumor or at other locations. The challenge in the development of new cancer therapies lies in the need to destroy malignant cells without the concomitant destruction of nearby normal cells. In the case of radiotherapy, the dose required to destroy cancer cells is so enormous that neighboring normal cells are severely affected.48 The key limitation in the use of radiation is normal tissue tolerance. Similarly, in the case of 5 
chemotherapy, adjacent normal cells are compromised during treatment of malignant cells.49 
§ 2.1.2 Basis for the Development of Binary Systems for Cancer Treatment Binary systems have originated from the need for selective and specific destruction of tumor cells. 1 •2 They involve the use of two components for the treatment of cancer. Each component is relatively harmless to mammalian cells, but their combination generates a highly lethal effect. A binary system is valuable because it allows each component to be manipulated independently. For this approach to succeed, it is vital that at least one of the components be limited specifically to the tumor cells while the second component may be exposed to all cells in a particular area. Thus, knowledge of the precise location of tumor cells in order to achieve their destruction is not necessary. Several binary systems now in various stages of development include photon activation therapy,50 photodynamic therapy,5 1-53 use of radiation sensitizers,54•55 gene therapy,56•57 and neutron capture therapy (NCT). 1 .2. 1 3,ss-61 
§ 2.1.3 Principle of Neutron Capture Therapy Neutron capture therapy (NCT) is based upon the observation that there are certain nuclides, both radioactive and nonradioactive, whose nuclei possess a capacity for absorbing thermal or slow neutrons. 62 NCT has largely revolved around the use of nonradioactive nuclides.2 When boron-IO is the nonradioactive nuclide used, the technique is referred to as Boron neutron capture therapy (BNCT). 
6 
BNCT requires the site-specific delivery of large quantities of boron-10 to the tumor (>15 µg boron/g tumor).63 After deposition of the boron-10, the area is irradiated with thermal neutrons. These neutrons have energy of approximately 0.025 e V, which is below the level of energy required to ionize tissue components. However, the interaction of the thermal neutrons with the boron-10 nuclei results in the formation of two highly energetic species, a lithium ion and an alpha particle. 10 1 [ 1 1  ] B + n �  B __,..  5 0 5 He + 2 Li 3 + y 0.48MeV + 2.31MeV The linear energy transfer (LET) of these particles dissipates within 9-10 µm in tissue, the approximate diameter of a single cell .  Therefore, irradiation of sufficient quantities of boron-10 in the tumor cells should result in the destruction of tumor cells while normal neighboring cells remain essentially unaffected. 
§ 2.1.4 Rationale for the Choice of Boron as a Nuclide in Neutron Capture 
Therapy Boron-10 has a high capture cross section of 3838 barns (1 barn = 10-24 cm2) for thermal neutrons.64 This value is large by nuclear standards and exceeds the value for tissue elements like carbon, hydrogen, oxygen, and other normal tissue components by at least two orders of magnitude.64 An additional advantage of boron- IO is that many different boron compounds having hydrolytically stable linkages between boron and other elements such as carbon and nitrogen can be synthesized. In addition to covalent bonds with various 
7 
elements, there are boron clusters like polyhedral borane anions and carboranes, which possess significant hydrolytic and metabolic stability. Boron, by virtue of its small atomic size, can replace carbon in many organic structures, generating compounds that offer potential for simulating biologically those original compounds from which they are derived. Much of the activity in· the area of compound development for NCT has focused upon the use of boron- I 0. 2 The term Boron neutron capture therapy (BNCT) is thus widely seen as being synonymous with Neutron capture therapy (NCT). 
§ 2.1.5 History and Development of the Concept of BNCT Fermi observed the capture of slow ( or thermal) neutrons by certain nuclei . 65 The disintegration of these nuclei by interaction with the thermal neutrons was observed by Fermi and others, as well.66 By 1935, a good amount of experimental information collected showed that the ability of an atomic nucleus to capture a neutron was related not to the mass of the target nucleus, but to the actual structure of the nucleus. The concept of a characteristic effective cross-sectional area of the nucleus, expressed as units of 10-24 cm2 (known as barn units), was introduced. The effective nuclear cross-section of boron for neutron capture was known to be remarkably large. In 1935, Taylor described the capture of thermal neutrons by boron- IO nuclei followed by production of a lithium ion and an alpha particle.67 The translational range of the product ions was 1.1 cm in air with 2 Me V of kinetic energy distributed between them. 
8 
In 1936, Gordon L. Locher of the Bartol Research Foundation of the Franklin Institute in Philadelphia, Pennsylvania, first pointed out the potential medical applications of neutrons and Boron neutron capture (BNC).62 His concept invoked the simple neutron capture reaction by boron for a binary therapeutic method wherein a boron-IO nucleus contained in a compound that specifically localizes in · · ·  the tumor, and the thermal neutron, would be the two components of the binary system and the alpha particle and lithium ion would be the cytotoxic energetic reaction products. Locher' s concept of BNC was not realized for a long time due to unavailability of boron compounds for concentration in tumors and the absence of sources of low energy thermal neutrons. The first experiment took place in 1954 when William H. Sweet, a neurosurgeon at Massachusetts General Hospital (MGH) in Boston, and L.E. Farr, of the Brookhaven National Laboratory (BNL) Medical Department, attacked malignant human brain tumors using 1°B-enriched sodium borate as the target species in terminal patients.68•69 Five patients received a single radiation dose, and five received multiple fractionated doses. In 1959, the then new Brookhaven Medical Research Reactor was employed to treat sixteen more patients with 1°B-enriched borates as the target species.70•7 1  These trials were not particularly successful because the available boron compounds failed to localize selectively in the tumor cells. During the 1950s and early 1960s, numerous boron compounds were synthesized and evaluated for BNCT.72 The structures of some of these compounds are shown in Figure 2.1. These included boric acid along with its derivatives and 9 
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Figure 2.1 Compounds used in the initial clinical studies for BNCT 10 
substituted phenylboronic acids including 4-dihydroxyborylphenylalanine (BPA). During this time, polyhedral borane anions B10H102· and B12H 1/· were discovered and their chemistry was studied in great detail.73•74 Also, the icosahedral carboranes, 
closo-1 ,2- and closo-1,7-C2B1oH1 2, were synthesized and derivatives prepared.75 The remarkable kinetic stability of these polyhedral -ions and carboranes made them attractive candidates for BNCT. Of the compounds evaluated by Soloway for selective tumor accumulation, the sodium salts of B 1 2H1 1SH2- (BSH) and 1,10-B 1 0Cl8(SH)/· stood out with the former being sufficiently non-toxic to merit further study. Japanese neurosurgeon, Hiroshi Hatanaka, initiated a clinical trial with Japanese brain cancer patients using 1°B-enriched sodium mercaptoundecahydrododecaborate (Na2 1°B 1 2H1 1 SH, BSH) and thermal neutron beams of low intensity.76 Out of the thirty eight patients treated, the reported mean survival was forty four months, significantly longer than the twelve month survival rate attainable using chemotherapy and radiation therapy. Among the long term survivors were a 70-year old woman, a 65-year old man, and a 13-year girl, who were unaffected twenty years later and appeared to be completely cured. Hatanaka's results were good and kindled an interest in BNCT around the world. The European Collaboration was formed and began treating patients in the late 1980s.77 Clinical trials are now continuing in Japan, are underway in the United States, and a new trial has begun in Europe.78-8° Centers in Sweden and Finland are now accepting patients. NCT centers and neutron sources are currently being 11 
constructed in Hungary, Czech Republic, China, Taiwan, Thailand, Slovenia, and South America. 8 1  
§ 2.1.6 Potential BNCT Agents The success of BNCT depends on the development of compounds that possess the following attributes: (1) an ability to target tumor cells selectively in the presence of normal cells; (2) sufficient concentration levels in the range of 20-35 µg 
1°B per gram of tumor; (3) demonstrate tumor to normal tissue ratios greater than 1 and preferably 3-5 ; (4) show tumor to blood ratios of greater than 1 and preferably higher; and (5) are non-toxic so that the dose administered is well tolerated in patients. In the early years of BNCT (1940-1961), only those compounds were considered that were either readily available commercially or easily synthesized. These compounds were evaluated exclusively for the treatment of brain tumors. Since then, other tumors have been considered. Although BSH and BPA are the only compounds currently being used in clinical trials, many groups have been diligently working on the design and synthesis of new tumor-targeting boron entities. Some of the classes of compounds being explored are presented below. 
§ 2.1.6.1 Amino acids The interest in the development of boron-containing amino acids arises from 4-dihydroxyborylphenylalanine (BPA), one of the two clinically used BNCT agents. In addition to the para-isomer of BPA,61 •82 the ortho- and meta- isomers have been 12 
synthesized and evaluated. 83•84 Figure 2.2 contains the dihydroxyboryl analogues of phenylalanine. In order to increase the water solubility of BPA, many hydrophilic groups have been incorporated into its structure as shown in Figure 2.3 .3•85•86 An interesting modification- of-BP A has been the addition of a carborane cage to the molecule. These polyhedral compounds permit higher percentages of boron in the molecule. Many different carborane-containing amino acids have been synthesized and evaluated. 81-90 Some of these are shown in Figure 2.4. Our research group has explored non-naturally occurring cyclic amino acids.9 1 •92 
§ 2.1.6.2 Peptides The principle for the synthesis of boron-containing peptides was based on the possibility that small peptides might cross cellular membranes and be utilized by tumor cells. Boron-containing di- and tripeptides derived from zwitterionic borane­containing amino acid analogues are shown in Figure 2.5.93 There has been an emphasis on developing peptides containing polyhedral borane anions. 
§ 2.1.6.3 Nucleosides, Nucleotides, and Nucleic Acids Nucleosides and nucleotides are building blocks for nucleic acids and are involved in many biological pathways.94 Compounds in this class are made up of a sugar, an azo base, and a phosphoric acid. Nucleosides do not have the phosphorus component. The most well known nucleic acid is deoxyribonucleic acid or DNA. This class of compounds is being studied as potential BNCT agents due to its 1 3  
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17  
importance in the building of cells. It has been estimated that, by introducing boron into the cell nucleus via DNA, the effectiveness of BNCT would double.95 One approach in this direction was to attach the boron moiety directly on a pyrimidine nucleus. This work led to the synthesis of 5-(dihydroxyboryl)uracil, carborane­containing pyrimidines, and subsequently led to the first boron-containing · · · nucleoside, 5-(dihydroxyboryl)-2' -deoxyuridine (DBDU).96-98 The structures of these compounds are shown in Figure 2.6. A number of boron and carborane-containing nucleoside derivatives were also synthesized.99• 1 00  Representative compounds are shown in Figure 2.6. In addition to nucleosides, nucleotides have also been prepared and biologically evaluated. 101 • 1 02 
§ 2.1.6.4 Porphyrins Porphyrins are extremely important compounds in biological systems. Hemoglobin and all varieties of chlorophyll contain some type of porphyrin. Porphyrins are currently used in a binary cancer treatment known as Photodynamic therapy (PDT).5 1 •52 PDT studies have shown that porphyrins tend to localize in tumor cells and remain there indefinitely. A porphyrin of significant interest to scientists for BNCT is shown in Figure 2.7. 103•1 04  
§ 2.1.6.5 Liposomes Liposomes are spherical lipid bilayers that form in aqueous media. The membrane bilayer is shown in Figure 2.8. Liposomes have a large affinity for cancerous tissue and are often used to deliver highly polar medications.105 Small 1 8  
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unilamellar liposomes have been shown to penetrate the tumor cell membrane and localize intracellularly. Incorporating boron compounds within them would provide a basis for achieving selectivity between tumor and normal cells. 16  The compound is incorporated either into the aqueous core of the liposome or into the membrane bilayer. BSH, various polyhedral boron compounds, and highlypolar amines have · been encapsulated in liposomes and appear to have significant potential as BNCT agents. 15  Boronated derivatives of naturally occurring steroids like cholesterol have also been encapsulated. 106 
§ 2.1.6.6 Carbohydrates Compared to normal cells, the carbohydrate composition of the cell membrane surface of malignant cells differs greatly. 107 Incorporation of the carbohydrate moiety increases a compound's  aqueous solubility. Boron and carborane-containing analogues of glucose, mannose, ribose and gulose have been prepared as shown in Figure 2.9. 14•99 It is hoped that such structures may achieve elevated concentrations in tumors through the action of glucose transport system. 108 
§ 2.2 CYCLOOXYGENASE-2 (COX-2) ENZYME INHIBITORS AND THEIR 
ROLE IN HUMAN COLORECTAL CANCER This section describes the history and background of the cyclooxygenase-2 enzyme inhibitors and our rationale for their choice as potential BNCT agents. 22 
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Figure 2.9 Carborane-coittaining analogue of carbohydrates 23 
§ 2.2.1 Colorectal (colon) Cancer Colorectal cancer is the third most common cancer in the world and is second only to lung cancer as the cause of cancer deaths in the United States. 109 This high rate of mortality calls for effective means of combating the disease. Over the past two decades, a large amount of research work has been initiated in this field including studies on the molecular genetics of colon cancer. 1 10 Significant attention has been given to the development of chemopreventive agents.24•25• 1 1 1- 1 13 
§ 2.2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Inflammation is the reaction of living tissues to injury. It involves a complex series of enzyme activation, mediator release, discharge of fluid, cell migration, tissue breakdown, and repair. 1 14 Anti-inflammatory agents date back to ancient times when a variety of plant extracts containing salicylates were used for the treatment of inflammation, fever, and pain. 1 15 Aspirin, the acetylated derivative of salicylic acid, was introduced in 1899. 1 16 Aspirin is derived from salicin, a naturally occurring compound found in white willow tree bark and other plants. Use of salicin as a pain reliever goes back to the 5th century B.C. when its use was described by Hippocrates. However, it was noted that aspirin had risks when taken over a long period of time. Long-term aspirin use led to the development of ulcers, serious gastrointestinal bleeding (GI), and damage to the kidney. Closely related NSAIDs like ibuprofen and naproxen were subject to the same GI and renal effects. 1 17 For many years, research was conducted to comprehend how aspirin and other NSAIDs work. In 1971, John 
24 
R. Vane, a British pharmacologist, proposed that the mechanism of aspirin-like drugs was through inhibition of prostaglandin synthesis from arachidonic acid via blockage of the cylooxygenase (COX) enzyme. This pathway is shown in Figure 2.10. 1 18 His group also demonstrated that aspirin interferes with the formation of blood clots by inhibiting aggregation of platelets. It was-this observation that subsequently stimulated research into aspirin's potential for preventing heart attacks and recurrent small strokes. For this work, John Vane received a share of the 1982 Nobel prize in medicine. The studies conducted by Vane generated great interest in the interaction between NSAIDs and the enzyme known to pharmacologists as cyclooxygenase (COX). 
§ 2.2.3 Cyclooxygenase (COX) Enzyme COX, also known as Prostaglandin H Synthase (PGHS), is the enzyme which catalyzes the first committed step of prostaglandin production - the conversion of arachidonic acid into Prostaglandin H2 (PGH2). 1 19 Prostaglandins are potent mediators of important physiological processes in the body. In the early 1990s, two isoforms of the COX-enzyme were identified, COX-1 and COX-2. 1 20• 1 2 1  COX-1 is constitutively expressed in most tissues and synthesizes prostaglandins for normal physiological functions like renal blood flow regulation, maintenance of microvascular integrity in the gastrointestinal tract, regulation of cell division, and the production of mucus. On the other hand, COX-2 is swiftly and radically induced 
25 
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26 
in response to cytokines, tumor prompters, and growth factors; all of which are thought to play a critical role in the initiation and maintenance of cancer cell survival and growth. 122-1 24 Long-term use of NSAIDs has been associated with side effects like renal toxicity, gastrointestinal ulceration, and increased bleeding. 1 25 CurrentNSAIDs such . as aspirin, sulindac, and indomethacin have little selectivity for inhibition of either COX-1 and COX-2. 1 26 In fact, it was suggested that the anti-inflammatory action of NSAIDs may be due to the inhibition of COX-2, whereas the toxic effects on the stomach and kidney were due to the inhibition of the constitutive enzyme, COX-1. 1 27 The above observation led to the possibility that selective inhibitors of COX-2 would have the usual beneficial effects of NSAIDs without the toxic side effects associated with the latter. The pharmaceutical industry invested immense resources in an effort to develop, test, and market a selective COX-2 inhibitor. Monsanto/ Searle introduced celecoxib (celebrex) in 1999 for rheumatoid arthritis and osteoarthritis, Merck followed with rofecoxib (vioxx) and it is now believed that GlaxoSmithKline, Johnson and Johnson, Novartis, Parke Davis, Roche, Boeringer­Ingelheim, Abbott Laboratories, Procter and Gamble, Dupont, American Home Products, Japan Tobacco, and Fujisawa all have active development programs. 1 17•1 28 The major classes of COX-2 inhibitors will be discussed briefly in Section 2.2.4. X-ray crystallography of the 3-D structure of COX-1 and COX-2 has provided the basis for logical drug development for selective COX-2 inhibition. 129 X-ray studies have shown that COX-1 and COX-2 are similar enzymes consisting of 27 
a long narrow hydrophobic channel. NSAIDs block COX-1 about midway down the channel and this blocking occurs by hydrogen bonding to the polar arginine at position 120. 128 Arginine 120 is also present in COX-2. A single amino acid difference is critical for selectivity of many drugs: at position 523 is an isoleucine molecule in COX-1 and a.valine molecule (smaller by a single methyl group) in COX-2. This smaller molecule in COX-2 leaves a gap in the wall of the channel, creating a side pocket, which is thought to be the site of binding of many selective drugs. The bulky isoleucine at 523 in COX-1 is large enough to block access to the side pocket. It has been shown that targeted single amino acid substitution of valine for isoleucine is sufficient to turn COX-1 into an enzyme that can be inhibited by a COX-2 selective agent. 1 30 
§ 2.2.4 Major Classes of COX-2 Inhibitors 
§ 2.2.4.1 Thiazoles Boehringer-Ingelheim' s meloxicam is the most well known member of this group of compounds. 1 3 1  Searle has developed compound 1 which has shown potent activity against COX-2 and is in the process of being studied further. 1 32 Both these compounds are shown in Figure 2. 1 1 .  
§ 2.2.4.2 Oxazoles Oxazoles are related to thiazoles in that the sulfur in the five-membered ring is replaced with an oxygen atom. Compound JTE-522 shown in Figure 2. 12 is a 
28 
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potent, orally active, and highly selective COX-2 inhibitor, and is in clinical trials. 133 A series of oxazole-based inhibitors based on JTE-522 have been designed and investigated. § 2.2.4.3 1,5-Diarylpyrazoles Celebrex (SC-58635) shown in Figure 2.12 belongs to this class of compounds. 1 34 It is a highly selective COX-2 inhibitor and is currently in use for the treatment of rheumatoid arthritis and osteoarthritis. It requires the presence of either a sulfonamide or a methylsulfonyl moiety for COX-2 potency. This class of compounds will be discussed in greater detail in Chapter 4. § 2.2.4.4 3,4-Diarylfuranones Vioxx (MK-0966) is a member of this class of compounds and a very potent COX-2 inhibitor. 1 35 Merck has recently modified this furanone ring system by introduction of a hydroxyl group in the 5-position of the diarylfuranone ring system providing water-soluble, highly selective COX-2 inhibitors which facilitate intravenous formulations. 136 Merck has also developed another compound named DFU, which shows promise as a COX-2 inhibitor. 137 These compounds are shown in Figure 2.12. § 2.2.4.5 Ethers and Thioethers Nimesulide 138 and NS-398 139 are well known members of this group of compounds. They have been introduced as pain relievers. Flosulide 140 and L-31 
745,337 141 are also well established anti-inflammatory agents belonging to this group 
with the latter exhibiting a better pharmaceutical profile than the former in in vivo 
studies. These compounds are shown in Figure 2. 13 .  
§ 2.2.4.6 Fused Heterocycles 
The COX-2 inhibitors in this class include analogues of imidazothiazole, 142 
thiazolotriazoles, 143 thiazolofuranones, 144 and imidazopyridines 145 • Examples of 
these compounds are shown in Figure 2. 14. Of these, the thiazolotriazole, with its 
lactone ring, has the ability to function as a pro-drug in which the ring can be opened 
to the active hydroxycarboxylate. 
§ 2.2.4. 7 Cyclopentenes 
1 ,2-Diarylcyclopentene methyl sulfones belong to this class of compounds. 
They are reported to be orally active, highly potent COX-2 inhibitors. 146 An example 
of this family, compound 2, is shown in Figure 2. 15 .  
§ 2.2.4.8 Cyclobutenones 
2,3-Diarylcyclobutenones is a member of this class of COX-2 inhibitors. 147 
Compound 3, shown in Figure 2. 15,  is an example of this family. 
§ 2.2.4.9 Cyclopentenones 
Merck is exploring 2,3-Diarylcyclopentenones as orally active, highly 
selective COX-2 inhibitors. 3 ,5-Difluorophenyl derivative (L-776,967) and 3-Pyridyl 
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35 
derivative (L-784,506), shown in Figure 2. 16, belong to this class of compounds. 148 Both these compounds exhibit good oral bioavailability and could be potential anti­inflammatory agents. 
§ 2.2.4.10 Pyrimidin-2-amines The Glax.o group recently reported Pyrimidin-2-amines as selective inhibitors of COX-2. 149 An example of this class, compound 4, is shown below in Figure 2. 17. 
§ 2.2.4.11 Pyridazinones Two highly selective and orally active COX-2 inhibitors belonging to this class of compounds have been identified by the Merck group. 150 The structures of these two compounds, 5 and 6, are shown in Figure 2. 17. 
§ 2.2.4.12 2,3- Diarylbenwpyrans AmorePacific Corporation in South Korea has synthesized 2,3-Diarylbenzopyran as a new class of COX-2 inhibitors with naturally occurring flavone as the main skeleton. 1 5 1  Compound 7 shown in Figure 2. 18  has been identified as a potent, orally active COX-2 inhibitor. 
§ 2.2.4.13 1,1-Dihalo-2,3-Diphenylcyclopropanes (Z)- and (E)-1 , 1 -dihalo-2-(4-substituted-phenyl)-3-phenylcyclopropanes have been synthesized and evaluated for potential COX-2 inhibitory activity. 152 An 36 
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39 
example of this class, compound 8, is shown in Figure 2.18. This group of compounds exhibited significant analgesic activity. 
§ 2.2.4.14 COX-2 lnhibitors from Natural Products Studies are in progress to find COX-2 inhibitors from natural products. COX-2 inhibitory activity has been observed in withanolide glycosides isolated from Withania somnifera leaves, 153 in prenylated flavanoids isolated from the leaves of Macaranga conifera, 154 and in prenylated chalcone derived from Humulus lupulus L.155 The methanol extracts of some natural products derived from Belamcandae rhizama and Gleniae radix have shown over 85% inhibition of COX-2 activity. 156 
§ 2.2.5 NSAIDs and Colorectal Carcinogenesis In 1988, Kune et al. documented that regular users of aspirin, a NSAID, had a 40% lower risk of the incidence of colon cancer compared to those who used no aspirin. 157 In 1994, Eberhart et al. first recorded the increased expression of the COX-2 enzyme in 85% human colorectal carcinomas (malignant growth arising in the lining of the colon). 123 This finding was later confirmed by other researchers. 127• 158 In 1995, Kargman et al. examined the expression of human COX-1 and COX-2 protein in 25 matched normal colon tissues and 25 colon cancer tissues. Their studies revealed that the COX-1 protein was present in all normal and tumor tissue whereas the COX-2 protein was not present in 23 of the 25 normal colon tissues but was present in 19 of the 25 colon tumors. 40 
An early clue that NSAIDs might be beneficial in the treatment of colon cancer came from a case study in which the NSAID sulindac caused elimination of rectal polyps (mass of tissue protruding outward from a normal surface) in a patient with Gardner's syndrome (a condition wherein several polyps present within a person are predisposed to form cancerous tissue in the colon). 159 Many laboratory animal model studies have indicated that NSAIDs such as sulindac, indomethacin, piroxicam, ketoprofen, and ibuprofen inhibit chemically induced colon cancer by suppressing the incidence and multiplicity of colon tumors.35 • 1 1 2• 1 1 3 • 1 59• 1 60 One of the most compelling pieces of evidence that NSAIDs can inhibit colorectal cancer cell growth came from a randomized, double-blind, placebo controlled clinical trial in patients with the hereditary colon cancer syndrome, familial adenomatous polyposis 
(F AP). F AP is a genetic disease with numerous precancerous polyps in the colon and rectum. Patients with FAP possess a germline mutation in one of the alleles of the tumor suppressor gene, adenomatous polyposis coli (APC). This causes them to develop polyps throughout their gastrointestinal tract very early in life. Unless the colon is removed surgically, one or more of these polyps develop into malignant tumors. 16 1 It is noteworthy that sulindac significantly reduced the number and size of colon polyps in FAP patients who are genetically predisposed towards colon cancer. I 62-164 This trend was reversed when therapy was terminated. 
41  
§ 2.2.6 Specific COX-2 Inhibitors and Colorectal Carcinogenesis All the studies described in Section 2.2.5 were conducted with NSAIDs that inhibit both COX-1 and COX-2. COX-2 was implicated in colorectal tumorigenesis when Oshima et al. treated Apct:.716 mice, a model of human FAP, with a novel COX-2 inhibitor. 165 Their results showed that the COX-2 inhibitor reduced polyp number more significantly that sulindac, which inhibits both COX-1 and COX-2. Oshima et al. also evaluated the chemopreventive activity of rofecoxib, a specific COX-2 inhibitor, in Apct:.716 mice model and found dose-dependent inhibition in the number and size of intestinal colonic polyps. 166 Studies conducted with celecoxib, a specific COX-2 inhibitor, on azoxymethane (AOM) induced colon carcinogenesis in rats indicated that continuous administration of 1500 ppm of Celecoxib in diet suppressed the incidence and multiplicity of AOM-induced malignant tumors by 93 and 97% respectively.35•38 This degree of inhibition by celecoxib was far greater than that reported with other NSAIDs like aspirin (40%), ibuprofen (45%), sulindac (50%), and piroxicam (70%). Prolonged administration of celecoxib did not induce any toxic side effects, such as gastrointestinal ulceration, bleeding, and weight loss, commonly associated with other non-specific NSAIDs that do not selectively target COX-2. Celecoxib has also been shown to decrease polyp size in mice. 167 Celecoxib has been demonstrated to be effective in inhibiting the incidence and multiplicity of polyps even at lower dose levels of 500 ppm (500 µgig of diet) and is an effective inhibitor of colon 42 
carcinogenesis even when administered at the progression stage of cancer at dose levels of 1500 ppm. 168 These observations raised the possibility that selective inhibitors of COX-2 could be a novel class of therapeutic agents for colon cancer and potentially serve as chemopreventive agents in colorectal carcinogenesis. Novel approaches for colon cancer prevention by COX-2 enzyme inhibitors are being studied. 169- 17 1 Research is also in progress on the development of colon-targeted delivery systems for celecoxib for the prevention of colon cancer. 172 For these reasons, we have focused our efforts on synthesis of boronated analogues of celecoxib as potential boron neutron capture therapy agents. Structures of some NSAIDs and specific COX-2 inhibitors are shown in Figure 2.19. 
§ 2.2. 7 Possible Mechanisms of Chemopreventive Effect of NSAIDs Several mechanisms have been put forth in literature to explain the anti­tumorigenic effects of NSAIDs.34• 1 73-177• There is definite evidence for the role of COX-2 in tumorigenesis. Inhibition of the cyclooxygenase enzyme and consequent reduction in prostaglandin levels is considered to be one of the main causes for the therapeutic effects of NSAIDs. Elevated levels of prostaglandins have been found in naturally occurring and experimentally induced cancers.22 Many reports in the literature have demonstrated that COX-2 mRNA was elevated both in human and experimental animal colorectal 
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tumors.48• 123•127 These observations, about the high levels of prostaglandins and COX-2 enzyme in tumor tissue, coupled with the chemopreventive effects of NSAIDs and specific COX-2 inhibitors, outlined in Section 2.2.5 and 2.2.6, strongly suggest that the anti-tumor effects of NSAIDs in colon cancer may be mediated by the inhibition of the COX-2 enzyme. It has also been suggested that NSAIDs may be acting in a prostaglandin (PG) independent manner. Sulindac was shown to cause regression of preexisting tumors in Mini+ mice independent of PG synthesis.37 Cell culture experiments showed that NSAIDs are able to induce apoptosis (process by which damaged or mutated cells in the colon are removed) in cells lacking the COX expression. 174 High doses of aspirin were shown to inhibit and destroy the pro-inflammatory factor, NF-KB, by an apparent PG-independent mechanism. 178 There is also evidence in the literature demonstrating that NSAIDs attenuate proliferation of colon carcinoma cells by inhibiting calcium capacitative entry (CCE) and altering intracellular calcium levels. 179• 1 8° CCE is an influx of extracellular calcium to replenish intracellular calcium that is mobilized by cells.34 Elevated intracellular calcium levels in tumors in Ape Mini+ mice are normalized by piroxicam.1 8 1 NSAIDs are also reported to attenuate cell proliferation induced by epidermal growth factors (proteins which regulate cell growth in colon cancer cells when awry) independent of prostaglandin synthesis. 1 82 The precise mechanism underlying the chemopreventive effects of NSAIDs is still not clear. Prostaglandins are actively involved in cell growth and cellular 45 
transformations. Excess prostaglandins can facilitate tumor cell growth. Reports in literature support the fact that COX-2 plays a wide role in colorectal carcinogenesis. There is compelling evidence in literature supporting the principle that NSAIDs act via inhibition of prostaglandins and the COX enzyme. At the same time, there are conflicting reports. Thus, NSAIDs might be exerting their therapeutic effects via a number of mechanisms including inhibition of the COX-2 enzyme. 
§ 2.3 UNNATURAL CYCLIC AMINO ACIDS This section deals with non-naturally occurring cyclic amino acids and our rationale for their choice as potential BNCT agents. A brief overview of the history and development of boronated amino acids as potential BNCT agents is also presented. 
§ 2.3.1 4-Dihydroxyborylphenylalanine (BPA) BP A, shown in Figure 2.20, is one of two amino acid BNCT agents and is the only drug currently used in BNCT trials in the United States. BPA was first reported in 1958.1 83 Interest in BPA was generated when studies using neutron irradiation experiments found BPA to be potent against B- 16 melanoma (malignant tumors arising from the skin) in vitro and against Green's  melanoma in hamsters. 1 84 Further work with melanoma in pigs and humans also demonstrated the efficacy of BP A as a BNCT agent. 1 85 Studies conducted in mice showed that 1°B-enriched BP A achieved tumor concentrations of boron as high as 30 µg 1°Blg tumor. 1 86 46 
Figure 2.20 4-Dihydroxyborylphenylalanine (BPA) 
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Clinical trials with BP A for BNCT of human malignant melanoma have been undertaken in Japan. 1 87 The use of BP A against melanoma is based on the fact that the melanin pigment is synthesized in vivo from natural aromatic amino acids, phenylalanine and tyrosine. Due to this, melanoma cells incorporate both phenylalanine and tyrosine from extracellular fluid. 1 88 In order to understand the pharmacokinetics of 1°B-BP A in melanoma, studies were conducted using 18F labeled BPA, which was synthesized as a positron emitting tracer, and the concentration of this compound was assessed non-invasively in vivo by positron emission tomography (PET). 1 89 The selectivity of 1 8F labeled BPA for melanoma tumors was up to 8 times higher than normal tissue. The low aqueous solubility of BPA at physiological pH has been a constant impediment to its use. This problem has been overcome by converting BP A to water soluble boronate esters with carbohydrates, diethanolamine, and cyclodextrin derivatives. Selective tumor uptake of the BPA-fructose complex and a good tumor to blood boron concentration ratio has been observed in a recent clinical trial with melanoma patients. 1 90 BP A has also been shown to accumulate in mammary and brain tumors and has hence been proposed for the treatment of brain cancer. 1 88 Its potential in this regard has been attributed to its ability to cross the blood brain barrier. Studies conducted on a mouse brain model with the fructose complex of BP A showed that neutron capture therapy with BPA was a safe procedure for brain cancer. 191 BPA was proven effective in BNCT of intracerebral tumors in rats and mice. 1 92• 1 93 In a 48 
comparative study of BNCT and X-ray radiation for treatment of rat brain tumors, it was seen that the brains and blood vessels of the rats subjected to BNCT were normal and intact without any harm to surrounding tissue in contrast to the brains of X-ray radiation survivors who showed loss of neurons, leakage of the blood-brain barrier, deterioration of brain growth, and serious intellectual deficiencies. The therapeutic use of BNCT for brain cancer was thus established. Both 2- and 3- dihydroxyborylphenylalanine have been synthesized and are undergoing evaluation. 82 
§ 2.3.2 Amino Acids other than BPA L-Carboranylalanine, shown in Figure 2.21, an analogue of L-phenylalanine, is currently undergoing in vitro and in vivo studies for efficacy in BNCT. 194 The ammonium carboxyborane analogue of glycine, shown in Figure 2.21, wherein a neutral carbon atom is substituted by an anionic boron atom, has also been synthesized. 195 The blood-brain barrier is more permeable to this ammonium carboxyborane analogue than it is to glycine. A number of such analogues are being developed and evaluated for BNCT. 195 A different carborane-containing amino acid has been reported in which the amino and the carboxyl functions are positioned on separate carbon atoms of the carborane nucleus. 196 Another class includes unnatural cyclic amino acids which will be discussed in greater detail in the next section.92 
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coo-L-Carboranylalanine Glycine 
Figure 2.21 Amino acids other than BPA 50 Ammonium carboxyborane analogue of glycine 
§ 2.3.3 1-Aminocyclobutanecarboxylic acid (ACBC) and its derivatives It is believed that amino acids are preferentially taken up by growing tumor cells. ACBC has been known to be preferentially retained in intracerebral tumors.41 . 1 97 In addition, ACBC has been found to be non-toxic. It is known that 1-aminocycloalkanecarboxylic acids cross the blood brain barrier. 1 98 Positron emission tomography (PET) studies carried out on BNCT patients at the University of Tennessee using fluorine-18 labeled BP A and carbon- I I labeled ACBC showed that cyclic amino acids localized in glioblastoma multiforme (malignant brain tumors) to a greater extent than BPA.41 These properties paved the way for boronated ACBC analogues as potential BNCT agents in the treatment of brain tumors. Our research group has explored boronated, non-naturally occurring cyclic amino acids modeled after ACBC. We reported the synthesis of a series of 4-Dihydroxborylphenyl derivatives of ACBC. 1 99  Varying numbers of methylene units were introduced between the dihydroxyborylphenyl and the ACBC moiety with the aim of making the molecule more lipophilic. Synthesis of m-carborane-containing ACBC derivative and a less lipophilic nido analogue were also accomplished.91 •92 Incorporation of carboranes was thought to be advantageous due to their chemical stability and high boron content. However, the hydrophobic nature of the m­carboranyl derivative limited its in vivo use. The nido derivative provided good water solubility but the ionic character of the cage proved to be problematic in in vivo studies because it led to non-specific protein binding. To overcome this problem, a 51 
water-soluble, polyol containing m-carboranyl-ACBC was synthesized by our group. 200 Carbohydrates like galactose have also been incorporated into the carborane ring to increase water solubility.201 The structures of some of the above compounds are shown in Figure 2.22. For all the reasons aforementioned, we have focused our attention on the development of non-naturally occurring amino acids. All the compounds synthesized to date have been derivatives of ACBC. In our quest for unnatural cyclic amino acids as potential BNCT agents, we have accomplished the synthesis of l -amino-3-boronocyclopentanecarboxylic acid (ACPC) and l -amino-3-boronocycloheptanecarboxylic acid (ACHC). The synthesis of these molecules will be discussed in detail in Chapter 4. 
§ 2.4 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) This section deals with a brief overview of the SPECT technique and our rationale for radioiodination of an analogue of specific COX-2 inhibitor celecoxib as a potential SPECT agent for imaging tumors. 
§ 2.4.1 Development of SPECT Emission computed tomography (ECT) provides three dimensional distributions of radiotracers in vivo. These data are acquired from a series of two dimensional images taken from different views surrounding the patient.42 Early tomographic systems consisted of four thallium-activated sodium iodide crystal detectors surrounding the patient's head. There was a rotating chair to hold the 
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patient. The first emission tomographic system was developed in 1963.202 With the introduction of X-ray computed tomography and modifications in data interpretation, which accounted for such factors as scatter radiation, accurate ECT images of high quality were obtained. 203 
§ 2.4.2 Basic Principle of SPECT SPECT involves the detection of gamma rays emitted singly from radionuclides and the determination of the relative or absolute regional concentrations of these radionuclides as a function of time within small regions of the body. Some of the radionuclides that emit gamma rays include technetium-99m, thallium 201, iodine- 123, indium-11 1, and gallium-67. Iodine-123 is available widely in pure form without 1 241 contamination. 
§ 2.4.3 Factors Affecting SPECT A number of factors affect SPECT, which in tum affect the exact determination of the radionuclide concentrations. Some of these factors are radionuclide decay, biokinetics of radiopharmaceuticals, patient/organ motion and location, imaging systems, and reconstruction methods for the data.42 
§ 2.4.4 Instrumentation The instrumentation for SPECT consists of assemblies of thallium-activated sodium iodide detectors, which surround the patient. Lateral and rotational movement of the detector assembly permits different images of the patient. 
54 
Scintillation camera-based systems, wherein the patient is rotated in front of a stationary scintillation apparatus, are also used.204 
§ 2.4.5 Reconstruction of SPECT Images Along with technical factors like adequate analog to digital converters and spatial positioning of the assembly system with the patient, a variety of physical and mathematical factors need to be controlled for quality SPECT images. 205 SPECT data involve the accumulation of projection data consisting of a number of line integrals measured from different views around the patient. These data are reconstructed using algorithms_2<>6 The algorithm type most commonly in use involves mathematical equations that relate the projection and the source distribution. This method is referred to as filtered back-projection (FBP). 207 
§ 2.4.6 Future Development In addition to the development of new radiopharmaceuticals, better detectors that encompass a patient ' s  full body, new detector materials, powerful computers that make SPECT systems automated and easier to use, improved algorithms for reconstruction of images, and techniques to compensate for the scatter and other disturbances should make SPECT a very effective diagnostic tool for the detection of disease. 
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§ 2.4.7 Medical Applications of SPECT In principle, a chemically stable radiolabeled compound can be used for tumor imaging via SPECT and thus provide valuable information about a particular disease. SPECT has been used for quantitative estimation of malignant brain tumors.43 In vivo quantification of amyloid deposits in Alzheimer's disease using iodine-123 and iodine-125 labeled hydroxybenzothiazoles has been made possible via SPECT.208 A technetium-99m SPECT agent has been used in predicting multi­drug resistance gene expression levels in non-small cell lung cancer.45 SPECT has also yielded vital information about cognition in schizophrenic patients, and anti­depressant treatment effects in major depression.46•47 Our research group has been involved in the synthesis of potential SPECT agents for diagnostic applications in a variety of diseases. We have accomplished the synthesis of radiolabeled 9-amino-1,2�3,4-tetrahydroacridine (tacrine), shown in Figure 2.23, as a SPECT agent for Alzheimer's disease, to map the receptor sites of the enzyme acetylcholinesterase. Tacrine is a very potent and selective inhibitor of the acetylcholinesterase enzyme. It is known to be a cognitive enhancer in patients with Alzheimer's disease and has been approved for patient use. 209 The synthesis of 3-[2-(1-3- 1 231-iodobenzyl)-4-piperidinyl)ethyl]-1,2-benzisoxazole, shown in Figure 2.23 , was also accomplished for mapping the acetylcholinesterase enzyme.2 10 For diagnostic use in Jung cancer, we synthesized benzylidene derivatives of anabaseine, an active and non-toxic binding ligand for o.7-nAChR. The latter is 56 
1 1 23 Tacrine Benzisoxazole derivative 
Figure 2.23 Radiolabeled tacrine and benzisoxazole as potential SPECT agents 
for Alzheimer's disease 57 
known to be expressed in cell lines derived from small lung carcinoma. 3-(2,4-Dimethoxy-5-[ 123I]iodo)benzylidene)anabaseine was synthesized via a tin pre�ursor as a potential SPECT agent.21 1 An iodine-123 labeled analogue of COX-2 inhibitor celecoxib was accomplished, for diagnostic use in colon cancer, via radioiododestannylation of the tin precursor using peracetic acid. 212 
§ 2.4.8 Synthesis of Radioiodinated Aryl Iodides via Boronate Precursors The synthesis of radiopharmaceuticals requires suitable precursors. A variety of organometallic reagents like tin, silicon, lead, etc. have been used in this regard.213 Our research group has explored the possibility of organoboranes as precursors to radiopharmaceuticals for over two decades.44•21 4 Initially, boronic acids were used as precursors but the highly basic conditions associated with their synthesis precluded their use in the creation of radiopharmaceutical precursors containing reactive substituents like esters and ketones.44 Organotin reagents, which have been versatile precursors for a variety of radiopharmaceuticals, proved to be toxic; which created an impediment in their use in radiopharmaceutical production. 2 1 5  Thus, in pursuit of halodeboronation as a feasible approach to radiophannaceuticals, we reported the synthesis of arylboronate esters and their direct radioiodination to generate iodine-123 labeled products.216 A facile and direct synthesis of an iodine-1 23 labeled analogue of celecoxib using the above organoboronate ester technology for radioiodination was 58 
accomplished, thereby avoiding the use of toxic tin precursors in nuclear medicine. The synthesis will be discussed in greater detail in Chapter 4. 59 
Chapter 3 Research Objectives § 3.1 SYNTHESIS OF BORONA TED ANALOGUES OF COX-2 INHIBITORS AS POTENTIAL BNCT AGENTS AND PRECURSORS TO TUMOR IMAGING SPECT AGENTS The clinical success of BNCT depends on effective delivery of a sufficient quantity of boron to the targeted tumor site. Although BNCT has potential as a cancer treatment, results to date in the United States have been moderate at best. This has been due to the lack of a suitable boron carrier, which can selectively deliver high concentrations of boron to the tumor. From Chapter 2, Section 2.2, it is seen that elevated levels of the COX-2 enzyme have been found in colon tumor tissue and not in normal colon tissue. It can therefore be concluded that highly specific COX-2 inhibitors like celecoxib could be used to deliver boron to the tumors. This dissertation deals with the strategies and synthesis of boronated analogues of celecoxib, and also demonstrates the use of these boronated compounds as precursors in the synthesis of radiolabeled analogues as potential tumor imaging agents via SPECT. Representative examples of the analogues are shown in Figure 3 . 1 .  Synthesis of boronated monosubstituted analogues and progress towards the synthesis of disubstituted analogues is discussed in Chapter 4. The synthesis of the radiolabeled analogue is outlined in Chapter 6. 61 
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Figure 3.1 Boronated and radiolabeled analogue of celecoxib 
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§ 3.2 SYNTHESIS OF UNNATURAL CYCLIC AMINO ACIDS AS 
POTENTIAL BNCT AGENTS 4-Dihydroxyborylphenylalanine, an amino acid, is one of the two clinically used BNCT agents. Also, as mentioned in Section 2.3, 1-aminocyclobutanecarboxylic acid is preferentially retained in intracerebral tumors. Thus, amino acids serve as attractive targets for delivery of boron to the tumor site: This dissertation deals with the synthesis and preliminary evaluation of boronated 1-aminocyclopentanecarboxylic acid (ACPC), and 1-aminocycloheptanecarboxylic acid (ACHC), as potential BNCT agents. Progress towards the synthesis of a cascade polyol derivative of carborane-containing analogue of ACPC is also discussed. The synthetic strategy for these analogues is outlined in Chapter 5. Structures of ACPC and ACHC are shown in Figure 3.2. 63 
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Chapter 4 Synthesis of Boronated 
Analogues of a COX-2 
Enzyme Inhibitor This chapter seeks to explain the basis for the choice of target compounds for this dissertation from a structural perspective. It also describes the synthesis of the monosubstituted boronated analogues of celecoxib and explains the strategy and progress made in the synthesis of the disubstituted analogues. 
§ 4.1 SYNTHESIS OF 1,5-DIARYLPYRAZOLES Celecoxib belongs to the 1 ,5-diarylpyrazole class of COX-2 inhibitors. It contains a tricyclic ring system with a central pyrazole ring. This section outlines the general methods for synthesis of a pyrazole ring and the different routes used in literature for the synthesis of the 1 ,5-diarylpyrazole ring system. 
§ 4.1.1 General Methods for Synthesis of Pyrazoles The synthesis of pyrazoles from 1 ,3-dicarbonyl compounds and hydrazine (or its derivatives) is the most widely used and general method for pyrazole synthesis. Acetylenic carbonyl compounds also react with hydrazine to form pyrazole ring systems. Aliphatic diazo compounds react with both acetylenic derivatives and malonic derivatives to form pyrazoles. A detailed account of the isomerism, general reactions, and syntheses of the pyrazole ring can be found in literature.2 17  
65 
§ 4.1.2 Existing Synthetic Routes for the Construction of the 1,5-Diarylpyrazole 
Ring System Literature examples for the synthesis of the 1 ,5-cliarylpyrazole ring system are outlined below. § 4.1.2.1 Synthesis via Epoxy Ketones This approach has been employed by Searle Pharmaceuticals, the makers of Celecoxib, for the synthesis of 1,5-diarylpyrazoles. 1 34 In this method, an cx.,p­unsaturated ketone 9 is oxidized to an epoxyketone 10, which is then condensed with the hydrochloride salt of (4-sulfamoylphenyl)hydrazine, 11, to form the 1,5-diarylpyrazole ring system as shown in Scheme 4. 1 This method works well for compounds which have an alkyl or an aryl group on the central pyrazole ring. § 4.1.2.2 Synthesis via 1,3-diketones Another method, also employed by Searle Pharmaceuticals, utilizes the Claisen condensation of an acetophenone derivative 12 with ethyl trifluoroacetate to generate the 1 ,3-diketone 13 which is then condensed with 11 to form the 1 ,5-diarylpyrazole ring system as shown in Scheme 4.2. This method is more suitable when a -CF3 or a -CHF2 group is on the pyrazole ring. § 4.1.2.3 Synthesis via Arylalkynones The alkenylation of an aromatic compound such as 14 with 4-ethoxy-1, 1 , 1 -trifluorobut-3-ene-2-one and ZnCh, followed by bromination with bromine in 66 
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Scheme 4.1 Synthesis of 1,5-diarylpyrazoles via epoxy ketones 
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Scheme 4.2 Synthesis of 1,5-diarylpyrazoles via 1,3-diketones 
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1 1  
chloroform, and dehydrobromination with potassium hydroxide in ethanol can be used to form the arylalkynone 15.2 1 8'2 1 9 15 then undergoes cyclocondensation with 
1 1  to form the 1 ,5-diarylpyrazole ring as shown in Scheme 4.3. Of the three synthetic routes outlined above, the second pathway utilizing 1 ,3-diketones was chosen as the basic route for the synthesis of boronated COX-2 inhibitors. Modifications in the synthetic route pertaining to reagent choice, reaction times, and purification methods were employed during the course of the synthesis as required. 
§ 4.2 STRATEGY FOR INCORPORATION OF THE BORON MOIETY 
INTO THE 1,5-DIARYLPYRAZOLE RING SYSTEM It was decided to incorporate the boron moiety into the ring in the form of a boronic ester. Organoboronic esters are generally thermally stab]e and can be iso]ated by distillation.220 Pinacol diboron esters have also been isolated by flash chromatography on silica gel.22 1 .222 Arylboronic esters and acids have classically been synthesized from Grignard reagents such as 16 (or lithium reagents such as 17) and trialkyborates 18, as shown in Scheme 4.4.223 These reactions can involve bis-alkylation leading to borinic acid derivatives and the formation of trialkyboranes. In 1995 , Ishiyama et al. reported the first one-step procedure for preparing aryl boronic esters, 21, from aryl halides, 19, outlined in Scheme 4.5 . 224 Their method utilized palladium(0)-catalyzed cross coupling of thermally stable bis(pinacolato)diboron esters, 20, with aryl halides to 
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yield the arylboronate species. The advantage of this method is that various functional groups such as ester, acyl, nitrile, and nitro moieties which need to be protected while using Grignard and lithium reagents, are easily tolerated and do not need to be protected. The aryl halides employed in the coupling reaction were either iodides or bromides. Later, Marcuccio et al. reported the synthesis of arylboronates, 24, using palladium(O)-catalyzed cross coupling of thermally stable, less sterically hindered bis(neopentylglycolato )di boron ester, 23, with aryl halides 22 under mild conditions, shown in Scheme 4.6. 225•221 The aryl halide used is an iodide or a bromide. The reaction tolerates a variety of functional groups including acyl, ester, nitrile, nitro, amide, carboxylic acid, sulfonic acid, and trifluoromethyl groups. Fluorides and chlorides were not effective in the coupling process. Due to the mild reaction conditions and the ability of the process to tolerate a variety of functional groups, it offered the best possibility for introduction of the boron moiety into the 1,5-diarylpyrazole ring system, and was, therefore, the method of choice. 
§ 4.3 RATIONALE FOR THE CHOICE OF THE STRUCTURES OF 
TARGET COMPOUNDS The reasoning behind the structures of the target molecules chosen for this dissertation work is outlined. 73 
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Scheme 4.6 Synthesis of arylboronates via bis(neopentylglycolato )di boron 
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§ 4.3.1 Structure-Activity Relationship Data Our rationale is based largely on the structure activity relationship (SAR) data generated by Searle Pharmaceuticals, makers of celecoxib. They synthesized a number of 1,5-diarylpyrazoles and evaluated them for COX-2 efficacy. 1 34 Several sites of modification around the pyrazo]e ring system were explored. They observed that the sulfonamide group on the phenyl ring at the I-position on the central pyrazole ring was very important for COX-2 inhibition as it showed superior in vitro and in vivo efficacy. The 3-position on the pyrazole ring system, shown in Figure 4.1, was fixed to be either -CF3 or -CHF2, as both these showed the same in vitro potency and selectivity, but greater than any other groups at the same position. The Searle group also made numerous modifications on the aryl substituent at the 5-position of the pyrazole ring. Their results revealed that this position offered the most flexibility with regards to maintaining COX-2 inhibitory activity. A number of monosubstituted and disubstituted 5-aryl derivatives were synthesized and evaluated. Introduction of substituents in the 2- and 4-positions of the 5-aryl ring (depicted as 2' and 4' in Figure 4.1) resulted in more p�tent COX-2 inhibition than substituents in 3-position. Substituents with halogen, alkoxy, and alkyl in the 4' -position of the 5-aryl ring seemed to show some COX- I activity, which was modulated, with little effect on COX-2 potency, by introduction of a substituent a to the para-electron donating group. 
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Figure 4.1 Structure of celecoxib 76 
§ 4.3.2 Structures of Target Compounds Based on the structure activity data outlined in Section 4.3.1, the target compounds chosen were A, B, C, and D modeled after COX-2 selective 1,5-diarylpyrazole analogues synthesized by the Searle group. Derivatives A and B could be visualized as analogues of A' and B', respectively. These structures are shown in Figure 4.2. A' and B'  exhibited COX-2 potency and selectivity very similar to celecoxib. A' exhibited ICso (µM) values of 17.8 for COX-1 and 0.01 for COX-2, while B' exhibited IC50 (µM) values of 31.3 for COX-1 and 0.056 for COX-2. These values compare favorably with corresponding IC50 (µM) values for celecoxib of 15 .0 for COX-1 and 0.04 for COX-2. Disubstituted derivatives C and D were chosen based on SAR studies wherein groups like methyl and methoxy in the 4' -position of the 5-aryl ring, with either halogens, methyl or methoxy a to them, exhibited COX-2 potency and selectivity. Derivatives C and D could be visualized as analogues of C' and D' respectively. C' demonstrates IC50 (µM) values of 27.6 for COX-1 and 0.027 for COX-2 whereas D' exhibits corresponding IC5o (µM) values of 17  .4 and 0.015. The structures of these compounds are shown in Figure 4.3 .  
§ 4.4 SYNTHESIS OF COMPOUND A This section describes the synthesis of 4-[5-[4-(5,5-dimethyl­[ 1,3,2]dioxaborinan-2-yl)-phenyl]-3-trifluoromethy1-pyrazol-1-ylJ-77 
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Figure 4.2 Monosubstituted boron-containing target compounds A and B 
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Figure 4.3 Disubstituted boron-containing target compounds C and D 
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benzenesulfonamide, A. The synthesis method for 1,5-diarylpyrazoles via 1,3-diketones, outlined in Section 4.1.2.2, was the basic route followed for the preparation of the target compound. 1 34 Discussions of the diverse methods attempted such as the use of different reagents and reaction conditions for 1,3-diketones, modifications to the boron moiety, and various methods for the synthesis -of halogenated starting materials for disubstituted analogues are presented in the following sections. The most feasible method was then chosen and employed for the synthesis of A, B, C, and D. Experimental details are provided in the Experimental Section. 
§ 4.4.1 Synthesis via a Boronated 1,3-Diketone In this method, the boron moiety was introduced in the initial stages of the synthesis to form a boronated diketone, l-[4-(5,5-dimethyl-[ 1,3,2]dioxaborinan-2-yl)-phenyl]-4,4,4-trifluoro-butane-1 ,3-dione, 27, which was condensed with the hydrazine hydrochloride 11  to yield A. Since it was decided to incorporate the boron moiety into the ring via the procedure of Ishiyama et al. 224 and Marcuccio et al. 225-221 outlined in Section 4.2, the presence of halogenated precursors in the synthetic route became necessary. Synthesis of compound A was attempted via boronated diketone 27 as outlined in Scheme 4.7. Commercially available 4-bromoacetophenone, 25, was treated with bis(neopentylglycolato )di boron, 23, to yield 1-[ 4-(5,5-dimethyl-[ l ,3 ,2]dioxaborinan-2-yl)-phenyl]-ethanone, 26. But efforts to generate 27 via 
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8 1  
Claisen condensation of 26 with sodium methoxide (NaOMe) in methanol (MeOH) failed. Changing reaction conditions by using excess base and longer reaction times failed to produce the diketone. The reaction mixture, monitored using thin layer chromatography (TLC) and gas chromatography, showed only starting material. This scheme was aborted and not investigated further; Alternatively, it was decided to synthesize 27 by first making the halogenated 1 ,3-diketone and then introducing boron onto it as depicted in Scheme 4.8. 28 was allowed to react with ethyl trifluoroacetate in refluxing methanol for 24 hours, which was the method used by the Searle group for synthesis of celecoxib. This approach failed to yield the diketone. The acylation was then attempted by refluxing 28 with sodium amide (NaNH2) in tetrahydrofuran (THF) as solvent, but the yields were low.228-230 Even excess sodium amide and ester did not improve yields. Finally, the acylation was attempted using methyl trifluoroacetate and sodium methoxide in methyl tert-butyl ether (MTBE) as solvent, with constant stirring at room temperature. The reaction was a11owed to stir continuously at room temperature and monitored with TLC and GC. After stirring for about 48 hours, disappearance of the starting material was observed. The reaction was worked up and the presence of product 4,4,4-trifluoro- 1 -(4-iodo-phenyl)-butane- l ,3-dione, 29, was confirmed. 1 34•23 1 Other methods for synthesis of 1 ,3-diketones are reported in literature.232•233 Compound 29 was purified by recrystallization and subsesquently allowed to react with 23 in the presence of palladium catalyst, 1 , 1  ' -
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Scheme 4.8 Synthesis of compound A via boronated diketone 27 
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bis( dipheny lphosphinoferrocene )dichloropalladium, PdCh( dppt), and potassium 
acetate (KOAc) in dimethyl sulfoxide (DMSO) to yield 27.224 Product 27 was used 
without further purification and condensed with 4-(sulfamoylphenyl)hydrazine 
hydrochloride (SO2NH2C6�NHNH2.HCI), 11 ,  to yield compound A, which was 
purified by column chromatography over silica gel using ethyl acetate and hexane as 
eluent. 
4-(Sulfamoylphenyl)hydrazine hydrochloride was synthesized by 
diazotization of sulfanilamide, 30, with sodium nitrite (NaNO2) followed by 
reduction with tin(II) chloride and purified by recrystallization, depicted in Scheme 
4.9.234 Towards the end of this dissertation study, commercially available 4-
(sulfamoylphenyl)hydrazine hydrochloride was used. The procedure outlined in 
Scheme 4.8 also worked well starting from 4' -bromoacetophenone. 
§ 4.4.2 Synthesis via Halogenated 1,3-Diketone 
In this procedure, the boron moiety was introduced in the last step of the 
synthesi s in contrast to the earlier method. The approach is outlined in Scheme 4. 10. 
Compound 28 was acylated using methyl trifluoroacetate and sodium methoxide, as 
described earlier in Section 4.4.1 , to form 29. After purification, 29 was condensed 
with 11 to form 4-[5-(4-iodo-phenyl)-3-tritluoromethyl-pyrazol- l -yl]­
benzenesulfonamide, 31 , along with the 1 ,3-diarylpyrazole isomer. Compound 31 
was purified by flash column chromatography over silica gel .  It was then treated 
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with diboron ester 23, KOAc, .and PdC]i(dppf) to form compound A, which was purified by column chromatography. This procedure was also attempted using brominated starting material 32, as depicted in Scheme 4. 1 1 .  All compounds in Schemes 4.10 and 4.11 were characterized by elemental analysis and nuclear magnetic resonance (NMR) spectra. · 
§ 4.4.3 Synthesis Overview Ishiyama et al. ,224 and Marcuccio et al. 225 had previously observed that aryl iodides were generally more effective than bromides in coupling with diboron esters. The same observation was made during this study where the aryl iodides, 1 ,3-diketone 29 and the benzenesulfonamide 31, coupled more effectively with the diboron ester than their bromine counterparts . Also, it was observed that introduction of boron moiety into the ring in the last step, outlined in Section 4.4.2, proved to be more effective than introducing it at the 1 ,3-diketone step, in terms of obtaining a purer product and producing better yields. Thus, from preliminary studies, it was concluded that the synthesis pattern outlined in Scheme 4. 10 was the most viable and was the general synthetic scheme employed for Compounds B, C, and D. 
§ 4.5 SYNTHESIS OF COMPOUND B The synthesis of 4-[5- [2-(5,5-dimethyl- [ 1 ,3,2]dioxaborinan-2-yl)-phenyl]-3-trifluoromethyl-pyrazol- l -yl] -benzenesulfonamide, B, was accomplished from 
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commercially available 2-iodoacetophenone as outlined in Scheme 4. 12. The same procedure used for the acylation of 4-iodoacetophenone was employed for 2-iodoacetophenone, 35, and worked well. Compound 35 was acylated with methyl trifluoroacetate and sodium methoxide in methanol at room temperature to form 4,4,4-trifluoro-1-(2-iodo-phenyl)-butane-1 ,3-dione, 36, in almost quantitative yield. Compound 36 was used in the next step without purification and condensed with 11  to form the 4-(5-(2-iodo-phenyl)-3-trifluoromethyl-pyrazol- l-yl]­benzenesulfonamide, 37. Compound 37 was treated with a mixture of diboron ester 23, KOAc, and PdCh(dppf) to yield compound B. Both 37 and B were purified by column chromatography. All of the intermediates were characterized by elemental analysis and NMR spectra. § 4.6 PROGRESS TOW ARDS SYNTHESIS OF COMPOUND C A discussion of the synthetic strategy for 4-[5-[3-(5 ,5-dimethyl­[ 1 ,3 ,2]dioxaborinan-2-yl)-4-methoxy-pheny1]-3-trifluoromethyl-pyrazol-1 -yl]­benzenesulfonamide, C, is presented in this section. Boronated disubstituted analogue C was synthesized and its structure confirmed by high resolution mass spectrometry (HR.MS) and NMR. However it was not isolated in pure form. The synthesis is outlined in Scheme 4. 13. To accomplish the synthesis of C, it was necessary to synthesize 3-iodo-4-methoxyacetophenone, 39, with the correct regiochemistry for iodine, thus 89 
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facilitating introduction of boron moiety into the ring. The Friedel-Crafts reaction235•236 is normally the method of choice for acylation of aromatic compounds, but it was not thought to be a viable option here due to formation of side products, as both the methoxy and the iodo group are ortho- and para-directors. Deiodination has also been observed in Friedel-Crafts reactions. 237•238 1 n 1997, Zupan et al. reported the room temperature regioselective iodination of aromatic ethers mediated by 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (F­TEDA-BF4) commonly called Selectfluor™. Their studies showed that the regiochemistry of iodination could be regulated by the solvent used, as shown in Scheme 4.14. Thus, this procedure afforded an excellent method for selective iodination of an activated aromatic ring either at the a-iodocarbonyl or the iodoaryl position. 239•240 Employing the above method, 4-methoxyacetophenone, 38, was iodinated using elemental iodine and F-TEDA-BF4 in acetonitrile to give 39 in good yield. Alternatively, the synthesis of 39 has also been reported by reaction of 38 with Iodine(IIO tris(trifluoroacetate)24 1 and from corresponding aryl bromides by reaction with nickel bromide and zinc catalyst (NiBr2-Zn).242 Compound 39 was purified by chromatography and subjected to Claisen condensation to give 4,4,4-trifluoro-1-(3-iodo-4-methoxy-phenyl)-butane- 1 ,3-dione, 41, which was then condensed with 11 to give 4-[5-(3-iodo-4-methoxy-phenyl)-3-trifluoromethyl-pyrazol-1-yl]-benzenesulfonamide, 42. Product 42 was purified 92 
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93 
by column chromatography and coupled with 23 to give compound C. The yield of 
C was only 41  %, possibly due to the steric effects of the ortho-methoxy and diboron 
ester group. NMR analysis revealed the presence of minor amounts of boronic acid. 
§ 4.7 PROGRESS TOWARDS THE SYNTHESIS OF COMPOUND D 
Progress towards the synthesis of 4-[5-[3-(5,5-dimethyl-[ l ,3 ,2]dioxaborinan-
2-yl)-4-methyl-phenyl]-3-trifluoromethyl-pyrazol- l-yl]-benzenesulfonamide, D, is 
outlined in this section. A pure sample of the iodinated benzenesulfonamide 
precursor was obtained. The synthetic strategy is outlined in Scheme 4. 15. 
The first step in the synthesis of D involved preparation of 3-iodo-4-
methylacetophenone, 45. A detailed study of Friedel-Crafts acylation of ortho-, 
meta-, and para-iodotoluene has been reported in literature.243 This study showed 
that acylation of ortho-iodotoluene afforded by-products like di- and tri -iodotoluenes 
and 4-iodo-3-methylacetophenone in major amounts along with the desired product 
45, hence this method was not thought feasible. The procedure of Zupan et al. , utilizing F-TEDA-BF4 and elemental iodine, used in Scheme 4. 14, was applied to 3-
iodo-4-methylacetophenone. 244 In contrast to the results obtained with the methoxy 
analogue, iodination with ortho-iodotoluene did not proceed regioselectively. This 
may be due to the fact that the aromatic ring was not as activated here as it was with 
the methoxy group. Both, a.-iodocarbonyl derivative 44 and the iodoaryl derivative 
45 were formed, shown in Scheme 4. 16. Presence of starting material 43 was also 
detected. These were found difficult to separate. Changing reaction times and using 
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excess iodinating agent and F-TEDA-BF4 produced similar results. 
Regioselectivity in iodination could not be achieved using the iodination 
procedures described above. Alternative procedures, using ortho-iodotoluene with 
functional groups in the para-position that could be transformed into the acetyl 
group via simple functional group manipulations, were desired. Fortunately, 3-iodo:-
4-methylbenzoicacid, 46, was commercially available and was converted into the 
desired product, 45, via acid chloride 47, as depicted in Scheme 4. 15 .  Thionyl 
chloride (SOCh) was used to convert the acid to the acid chloride 47. 245 Compound 
47 was then treated with lithium dimethylcuprate (I) , formed in situ from 
methyllithium and cuprous iodide, in diethyl ether at -78 °C to give the desired 
compound 45246·247 which was purified by column chromatography. Organocopper 
reagents are advantageous in that they are not known to add across carbon­
heteroatom multiple bonds, unlike organolithium reagents, and are also not known to 
form diketones and keto esters from acid chlorides, unlike organocadmium and 
organozinc reagents.248·249 
Compound 45 was subjected to acylation with NaOMe and methyl 
trifluoroacetate to form the desired diketone, 4,4,4-trifluoro- 1 -(3-iodo-4-methyl ­
phenyl)-butane-l ,3-dione, 48, which was allowed to react with 11  to form 4-[5-(3-
iodo-4-methyl-phenyl)-3-trifluoromethyl-pyrazol- 1 -yl] -benzenesulfonamide, 49. 
Product 49 was purified by column chromatography and characterized by elemental 
analysis and NMR spectra. 
The conversion of 49 to compound D has not yet been attempted. 
97 
§ 4.8 SUMMARY The research objectives of synthesizing compounds A and B were realized. The analogue C was synthesized, as confirmed by HRMS, but showed the presence of side product, probably the boronic acid. However, pure iodinated precursors, 42 and 49, required for the synthesis of compounds C and D respectively; were · synthesized and characterized by elemental analysis and NMR spectra. A potential diagnostic tumor-imaging agent for SPECT was synthesized from compound A. The synthesis of the radiolabeled analogue is discussed in Chapter 6. 98 
Chapter 5 Synthesis of Boronated Unnatural Cyclic Amino Acids A description of the synthesis of five- and seven-membered boronated unnatural cyclic amino acids is described in this chapter. Details of the progress made towards the synthesis of a cascade polyol carborane-containing analogue of the five-membered amino acid are also presented. 
§ 5.1 RATIONALE FOR THE CHOICE OF THE STRUCTURES OF 
TARGET COMPOUNDS The structures of the target compounds were chosen based on 1 -aminocyclobutanecarbox ylic acid (ACBC), a boronic acid shown in Figure 5. 1 .  A meta-carborane containing derivative of ACBC has also been reported.91 •92 It was decided to attempt to introduce the boron moiety directly on the five-membered ring instead of on the side chain as shown in Figure 5.2. This chapter contains a summary of the synthesis of l -amino-3-boronocyclopentanecarboxy1ic acid� E, and l -amino-3-boronocycloheptanecarboxylic acid� F� shown in Figure 5.2.250 
§ 5.2 SYNTHETIC STRATEGY 
It was decided to introduce the boronic acid moiety via a diboron reagent such as bis(pinacolato)diboron, 50. Diboron reagents are useful for the borylation of 99 
ACBC Boronic acid derivative of ACBC 
Figure 5.1 Boronic acid derivative of ACBC 
100 
E F 
Figure 5.2 Target compounds E and F 101 
unsaturated organic compounds and organic halides.25 1 •252 Palladium and platinum complexes are efficient catalysts for diboration of a]kenes,253 alkynes,254 enones,255 and conjugated dienes256 with diboron esters. 1,4-Addition of diboron reagents to a,�-unsaturated carbonyl compounds, though not extensively studied in literature, has been reported with platinum255 and copper257 catalyst. It was decided to utilize hydantoins for the introduction of the a-amino acid moiety.258·259 The synthesis of hydantoins would be attempted by the Bucherer-Bergs method of hydantoin synthesis starting from carbonyl compounds. This is one of the most extensively used methods for hydantoin synthesis and is effective for many types of carbonyl compounds. It involves use of ammonium carbonate (N}4)2CO3 and potassium cyanide (KCN) in aqueous ethyl alcohol. The carbonyl group of the starting enone could be used effectively for introducing the amino group, hence the Bucherer-Bergs method was the method of choice. A comprehensive review of the methods of synthesis of hydantoins can be found in literature.258 When hydantoins are hydrolyzed for relatively long periods of time, they form a-amino acids. Hydantoins are valuable in the synthesis of a variety of a-amino acids that are otherwise difficult to obtain. In fact, hydantoin synthesis of a-amino acids was first suggested as a general method by Wheeler and Hoffman and later used by them in the syntheses of tyrosine and phenylalanine. 260 The first report of the preparation of an a-amino acid from a hydantoin was by Urech in 1872.26 1 
102 
Hydantoins can be hydrolyzed to form a-amino acids with a variety of reagents including concentrated acids, barium hydroxide, and ammonium sulfide. The synthetic strategy involved reaction of 2-cyclopentene- 1 -one or 2-cycloheptene- 1 -one with diboron reagent 50, introduction of the boron moiety, synthesis of the hydantoin, and then hydrolysis of the boron ester to the boronic acid and the hydantoin to the amino acid. 
§ 5.3 SYNTHESIS OF COMPOUND E 1 -Amino-3-boronocyclopentanecarboxylic acid, E, was synthesized starting from 2-cyclopenten- 1 -one, 51, as outlined in Scheme 5.1. It should be noted that, though 1 ,4-addition of di boron reagents to cyclic enones have been reported, there has been no report of such an addition with 2-cyclopenten- 1 -one. Nevertheless, the methodology that had been applied to six- and seven-membered cyclic enones was applied to cyclopentenone. The first catalyst system used for 1 ,4-diboration with 51 was a combination of copper(I) chloride (CuCI) and tributylphosphine.257 This reaction did not work well with 51. Even after running the reaction for long periods of time, little product was observed. Changing the reagent quantities did not help. TLC and GC analysis revealed presence of starting material in each case. A rhodium based catalyst, chlorotris(triphenylphosphine)rhodium(I), was then examined.262 The yields with this system were also poor. GC analysis revealed formation of a number of side products. This method was abandoned. 103 
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Takahashi et al. reported the room temperature borylation of enones using 
copper(I) chloride and potassium acetate (KO Ac) in dimethyl formamide 
(DMF). 263•264 This method was applied to cyclopentenone 51 which did react to give 
52. Though the yields from this process were modest, they were better than those 
obtained from the rhodium and copper-phosphine catalyst. 
Product 52 was column purified and treated with (�)zCO3 and KCN to 
form the hydantoin 53, which, on purification, was subjected to hydrolysis with 
concentrated hydrochloric acid (HCl) at high temperature to yield the target amino 
acid E. 
§ 5.4 SYNTHESIS OF COMPOUND F 
1-Amino-3-boronocycloheptanecarboxylic acid, F, was synthesized using a 
similar synthetic strategy, outlined in Scheme 5 .2. 
2-cyclohepten- 1 -one, 54, was treated with 50 to form boronated 
cycloheptanone 55. This reaction produced better yields than the five-membered 
analogue. Compound 55 was purified and subjected to Bucherer-Bergs conditions for 
synthesis of the hydantoin 56. Compound 56, after column purification, was 
subjected to hydrolysis with concentrated HCI at 160 °C to form target amino acid F. 
§ 5.5 RATIONALE FOR THE CHOICE OF A CARBORANYL CASCADE 
POL YOL DERIVATIVE OF COMPOUND E 
As described in Section 2.3, carborane-containing amino acid derivatives 
have been synthesized in order to increase the boron content of the amino acids.92 
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But carboranes are lipophilic in nature. In order to solve the water solubility problem, cascade polyol derivatives of carboranes have been synthesized.3•86 The cascade polyol is a good water-solubilizing agent. It has no asymmetric centers, so no diastereomers are formed when it is bonded to the carborane cage which can bear chiral or racemic biologically active molecules.265 This offers a distinct advantage over other solubilizing agents like chiral sugars. Thus, it was decided to synthesize a meta-carboranyl analogue of l -amino-3-boronocyclopentanecarboxylic acid using a cascade polyol as part of the molecule. This target compound G is shown in Figure 5.3. 
§ 5.6 PROGRESS IN THE SYNTHESIS OF COMPOUND G The synthetic strategy for the compound is out1ined in Schemes 5.3, 5.4, and 5.5. It should be noted that the synthesis of this molecule has not been completed, but good progress has been made in that direction. Schemes 5.3 and 5.4 outline the synthesis of intermediates 64 and 70, which can then be coupled to form the target compound G. The final coupling sequence is outlined in Scheme 5.5. The synthesis of polyol tosylate intermediate 64 and of compound 69, required for coupling with meta-carborane, has been accomplished, and will be described in this dissertation work. The reaction scheme in Figure 5.5 for the coupling of the two intermediates has not yet been attempted. 107 
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Pol yo I tosylate 64 was synthesized first. Benzyl alcohol (BnOH), 57, was 
treated with epichlorohydrin 58, tetrabutylammonium bromide (Bu�{), and 
sodium iodide (Nal) to form 59.265 Intermediate 59 was then subjected to the same 
sequence to form the higher homologue 60. Compound 60 was allylated with allyl 
bromide, 61 , and sodium hydride (NaH) in DMF as a solvent to form alkene 62, 
which on hydroboration followed by oxidation, yielded the cascade polyol 63.200 
Polyol 63 was converted to the desired tosylate 64 by the action of para­
toluenesulfonic acid (p-TsOH) in pyridine (CJ{5N). 
266 
The synthesis of intermediate 70 was initiated from 2-cyclopentene-1-one. 
Michael addition of 51 with sodium ethoxide (NaOCH2CH3) and diethyl malonate 
furnished 65.267 The carbonyl group of 65 was protected as a ketal by treatment with 
ethylene glycol to give 66.268 Intermediate 66 was converted to the monoester 67 by 
basic hydrolysis of the diester moiety with potassium hydroxide (KOH) followed by 
thermal decarboxylation.269 Compound 67 was subjected to lithium aluminum 
hydride (LiAI�) reduction of the ester group to yield alcohol 68.270·27 1 Mesylation of 
68 yielded 69.259 
§ 5.7 SUMMARY 
The synthesis of five- and seven-membered amino acids has been 
accomplished. The biodistribution of these compounds is currently being evaluated 
in mice. For compound G, key cascade polyol intermediate 64 has been synthesized 
and pure mesylate compound 69 has been prepared for coupling with meta-
1 12 
carborane in order to generate the intermediate 70. The chemistry outlined in Scheme 
5.5 has been proposed for the coupling procedure and should provide a feasible route for the synthesis of the target molecule. 
1 1 3 
Chapter 6 Synthesis of an Iodine-
123 Labeled Analogue of 
a COX-2 Enzyme 
Inhibitor Radiolabeled compounds are important in diagnostic medical imaging as they permit noninvasive, in vivo, three-dimensional imaging of internal organs. The motivation for preparing a radiolabeled analogue of celecoxib as a potential SPECT agent for colon tumor imaging has been put forth in Sections 2.2 and 2.4. This chapter outlines the synthesis of radiolabeled analogue, compound H, shown in Figure 6. 1 ,  via an arylboronate precursor, A.  
§ 6.1 SYNTHETIC APPROACH 
§ 6.1.1 Iodine-123 Isotope Radiohalogens have been widely used in nuclear medicine. A number of radioiodination techniques have been developed due to the avai labil i ty of a variety of useful iodine isotopes.2 13 Iodine- 123 is a single photon-emitting isotope of iodine with a half-life of 13.2 hours. It is being widely used in medicine due to its decay characteristics and commercial availability. A number of 1 231-labeled agents, shown in Figure 6.2, have been effective in clinical investigations. 272•273 
1 1 5 
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Figure 6.1 Target molecule H and boronate precursor A 1 16 
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§ 6.1.2 Rationale for Use of Radio labeled Sodium Iodide in Radioiodination The reaction of organoboranes with molecular iodine was developed by Brown et al.214 This method involves use of sodium methoxide as a base and molecular iodine. It is not considered to be an effective radioiodination technique as the sodium methoxide can affect other functional groups in the molecule. Also, it involves the use of molecular iodine, which is dangerous (due to its volatility) and an expensive chemical form for iodine radioisotopes.21 3  Investigations into the mechanism of the reaction have shown that it proceeds via the electrophilic attack of iodine on an electron-rich organoborane complex. This meant that any electrophilic form of iodine could be utilized.275 A new iodine methodology using in situ oxidation of radiolabeled sodium iodide using mild oxidants such as chloramine-T was developed. 276 This methodology has been used in this dissertation work for the synthesis of the electrophilic species required for radioiodination. An important feature of this methodology is that it permits radioiodinations to be carried out on a 'no-carrier-added' basis which is important as it ensures that the quantity of labeled agent is kept below the pharmacological dosages during nuclear medicine procedures. 277 
§ 6.1.3 Rationale for Choice of Arylboronate Esters as Precursors for 
Radioiodinations Over the years, many organometallic reagents have been used as precursors for a variety of pharmaceuticals. Reagents based on tin, mercury, thallium, silicon, 1 18 
germanium, and lead have been used.2 1 3  Organotin reagents have been widely used but the toxicity of tin compounds, the rather harsh stannylation procedures, and the strength of the carbon-tin bond have been serious drawbacks in this process.215  Our research group has focused on the use of organoboranes as precursors to radiohalogenated pharmaceuticals. Initial -studies included the use of boronic acids and trialkyboranes as precursors. 214 The prerequisite arylboronic acids were prepared under highly basic conditions using aryllithium and arylmagnesium halides. These highly reactive reagents are not suitable for preparing pharmaceutical precursors containing reactive substituents like esters, and ketones. Attention was then focused on arylboronate esters as possible precursors for radioiodinated compounds. Our group reported the direct radioiodination of arylboronate esters using radiolabeled sodium iodide, shown in Scheme 6.1.2 16  The arylboronate esters were prepared under mild conditions using the procedure developed in our labs. 278•279 
§ 6.2 SYNTHESIS OF COMPOUND H The synthesis of compound H was accomplished starting from compound A using the boronate ester as precursor, as outlined in Scheme 6. 1 .  Arylboronate, A, was synthesized as outlined in Chapter 4, Scheme 4.10. No-carrier-added sodium iodide was allowed to react with chloramine-T in the presence of boronated compound A in THF to yield compound H, as shown in Scheme 6.2. The total 119 
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synthesis time was 3 hours. A detailed procedure is presented in the Experimental 
Section. 
§ 6.3 SUMMARY 
The synthesis of a radiolabeled analogue of a COX-2 inhibitor was 
accomplished in good yield, and with a high purity of 99.5% from an arylboronate 
prepared under mild conditions. Given the possible relationship of the COX-2 
enzyme and colon cancer, outlined in detail in Section 2.2, this agent and other such 
analogues could be used as potential SPECT agents for colon tumor imaging, 
physiological mapping, and studying in vivo pharmacokinetics, which could provide 
valuable information about the disease. 
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Chapter 7 Conclusions and Future 
Work § 7.1 CONCLUSIONS The syntheses of monosubstituted boronated analogues of celecoxib, A and B, were achieved. The synthesis of key iodinated benzenesulfonamide derivatives 42 and 49, required for the preparation of the di substituted boronated analogues of celecoxib, was also accomplished. A potential SPECT agent E was made from compound A. Unnatural cyclic amino acids, E and F, which mimic the tumor specific ACBC, were synthesized. § 7.2 FUTURE WORK Future work should focus on the evaluation of A, B, and radiolabeled analogue E in vitro and in vivo. Results from these studies can be correlated with their structures and provide clues in designing other target molecules. Incorporation of the carborane moiety into the COX-2 inhibitor structures should also be investigated. Efforts should be made for the isolation of pure compound C. The synthesis and isolation of D via boronated precursor 49 should be attempted. Results from the biodistribution study of E and F should be utilized for the design of other target boronated amino acids. The synthesis of carboranyl cascade 123 
polyol G should be pursued. The synthesis route for this compound, outlined in Scheme 5.5, should provide a feasible method for its preparation. 124 
Chapter 8 Experimental Section 
§ 8.1 GENERAL METHODS Proton (1H) and carbon (13C) nuclear magnetic resonance spectra were acquired either on a Bruker WP250 at 250. 13 and 62.89 MHz, or on a Varian Mercury 300 at 300.09 and 75 .46 MHz, or on a Bruker Avance 400 spectrometer at 400.04 and 100.59 MHz respectively. Chemical shifts are reported in parts per million (ppm) using residual protons in deuterated solvents and are referenced to tetramethylsilane. The splitting patterns are abbreviated as follows: s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, and m = multiplet. Boron ( 1 1B) NMR spectra ( 1H-decoupled) were obtained on a Bruker Avance 400 at 128 .38 MHz. In the case of 1 1B spectra, chemical shifts were measured with reference to an external BF3 ·etherate sample and resonances observed upfield of the reference were assigned negative chemical shift values. The mass spectral analyses were obtained on a VG Quattro II electrospray mass spectrometer. Elemental analyses were performed by Atlantic Microlab Inc . ,  Norcross, GA and are within ±0.4% of the theoretical values. Melting points were determined on a Thomas-Hoover melting point apparatus and are uncorrected. All commercial reagents were purchased from Aldrich Chemical Co. (Milwaukee, WI) and used as received without further purification unless otherwise noted. All solvents were reagent grade and were disti lled from appropriate drying 1 25 
agents under nitrogen atmosphere prior to use. Tetrahydrofuran and diethyl ether were distilled from sodium benzophenone ketyl. Benzene was distilled from calcium hydride and stored under nitrogen. Column chromatography was performed using silica gel (60 A, 32-63 mesh) obtained from Bodman Chemical, Aston, PA. Analytical thin layer chromatography (TLC) was performed using 250 µm silica gel plates obtained from Analtech, Newark, DE, which were visualized with ultraviolet illumination at 254 nm and phosphomolybdic acid or development in an iodine chamber. The pH of a solution was determined using Whatman pH Indicator Paper. All glassware, syringes, and needles were dried in an oven and cooled under nitrogen prior to use. 
§ 8.2 EXPERIMENT AL PROCEDURES FOR BORON A TED ANALOGUES 
OF CELECOXIB (A, B, C, AND D) 
§ 8.2.1 Synthesis of 4-(Sulfamoyl)phenylhydrazine hydrochloride, 11 .234 A suspension of su]fanilamide (1.72 g, 10.0 mmol) in 20 mL of concentrated HCI was cooled to -5 °C and diazotized with 0.69 g (10.0 mmol) of NaN02. After stirring for 30 min at -5 °C, the reaction mixture was added slowly to a cold solution of SnCh (5.69 g, 30.0 mmol) in 10 mL of concentrated HCI. The mixture was stirred for 45 min at 0 °C (ice bath) and the precipitate formed was filtered off. The crude product was recrystallized from a methanol/ether solution, and dried to give 1 .46 g (65.4%) of 11  as a white solid: 1H NMR (250 MHz, DMSO-d6) 8 7.01 (d, J = 8.8 Hz, 126 
2H), 7. 18  (s, 2H), 7.70 (d, J = 8.7 Hz, 2H), 8.8 1 (br s, lH), 10.33 (br s, 2H); 1 3C NMR (63 MHz, DMSO-d6) o 113.2, 127.0, 136. 1 ,  148.4. 
§ 8.2.2 Synthesis of 3-iodo-4-methoxyacetophenone, 39.240·280·28 1 To a solution of 4-methoxyacetophenone (4.55 g, 30.0 mmol) in 300 mL of CH3CN was added elemental iodine (3.89 g, 15.3 mmol) and l-fluoro-4-chloromethyl- l ,4-diazoniabicyclo[2.2.2]octane bis( tetrafluoroborate (F-TED A-BF 4) (10.63 g, 30.0 mmol). After stirring for 16 h at room temperature, the solvent was removed in vacuo, the residue was dissolved in 750 mL of CH2Ch. and the insoluble material filtered off. The solution was washed sequentially with 300 mL of 5% aqueous sodium thiosulfate pentahydrate and water. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography (20% ethyl acetate in hexane) to yield 6.33 g (76.4%) of 39; 1H NMR (250 MHz, CDCh) o 2.54 (s, 3H), 3.94 (s, 3H), 6.40 (d, J = 8.6 Hz, lH), 7.94 (s, J = 8.6 Hz, lH), 8.37 (s, lH); 1 3C NMR (63 MHz, CDCh) o 26.2, 58.5, 85.8 ,  109.9, 130.4, 1 3 1 .7, 140.0, 161 .6, 195.3. 
§ 8.2.3 Synthesis of 3-iodo-4-methylbenzoyl chloride, 47. 245 To 3-iodo-4-methylbenzoic acid ( 10.8 1 g, 40.0 mmol) 46 contained in a 100-mL round-bottomed flask fitted with an inverted drying tube packed with moistened glass wool was added SOCh (33.0 mL, 452.4 mmol). The reaction mixture was refluxed for 5 h and then cooled to room temperature. Excess SOCh was distilled out and the mixture was left to dry on a vacuum pump to yield 10. 18 g (90.7%) of 127 
product 47: 1H NMR (250 MHz, CDCh) 6 2.50 (s, 3H), 7.35 (d, J = 8.0 Hz, lH), 7.97 (s, J = 8.0 Hz, lH), 8.48 (s, lH); 13C NMR (63 MHz, CDCh) 6 28.5, 1 00.8, 129.8, 1 30.9, 1 32.0, 14 1 .3, 149.9, 166.4. 
§ 8.2.4 Synthesis of 3-iodo-4-methylacetophenone, 45.247·282 Into a dry three-necked, 100-mL round-bottomed flask equipped with a rubber septum and a magnetic stir bar was added of Cul (2.86 g, 15 .0 mmol). The flask was evacuated and filled with nitrogen. This purging procedure was repeated two more times. Freshly distilled anhydrous ether (50 mL) was added to the flask and the system cooled to -5 °C. Methyllithium ( 18.8 mL, 30.0 mmol) was added and, after about 10 min, the temperature was lowered to -78 °C. A precooled ethereal solution of 47 ( 1 .40 g, 5.0 mmol) was injected into the yellowish reaction mixture. After 40 min at -78 °C, anhydrous methanol (2.22 mL, 55.0 mmol) was added and the reaction allowed to reach room temperature. The mixture was poured, with stirring, into saturated aqueous ammonium chloride (NltiCl), the organic layer extracted with ether, washed with brine, dried over MgS04, and the solvent removed on a rotary evaporator to give a reddish brown liquid. The crude product was purified by column chromatography ( 10% ethyl acetate in hexane) to give 0.98 g (75.4%) of 45: 1H NMR (250 MHz, CDCh) 6 2.46 (s, 3H), 2.55 (d, 3H), 7.29 (d, J = 1.9 Hz, lH), 7.8 1 (d, J = 1.9 Hz, lH), 8.35 (s, lH); 1 3C NMR (63 MHz, CDCh) 6 26.9, 28.2, 101 .0, 1 27.9, 129.6, 136.2, 1 38.8, 146.9, 196.2. 128 
§ 8.2.5 Preparation of 1,3-diketones 29, 33, 36, 41, and 48 via Claisen 
Condensation of Acetophenone Derivatives with Methyl 
Trifluoroacetate. 134 
§ 8.2.5.1 Synthesis of 4,4,4-trifluoro-1-( 4-iodo-phenyl)-butane-1,3-dione, 29. To a solution of methyl trifluoroacetate (4.23 g, 33.0 mmol) in 60 mL of methyl tert-butyl ether (MTBE) was added 25% NaOMe in MeOH (8.82 mL, 39.0 mmol). A solution of 4-iodoacetophenone (7.382 g, 30.0 mmol) in 1 1 5 mL of MTBE was added to the mixture dropwise via an addition funnel . After stirring for 48 h at room temperature, aqueous 3 N HCl (14.0 mL) was added. The organic layer was extracted with ether, washed with water and then brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo to give a brownish solid which was recrystallized from isooctane to give 8. 1 1  g (78.9%) of product 29: mp 37 °C; 1H NMR (250 MHz, CDCh) 8 6.53 (s, lH), 7.64 (d, J = 8.5 Hz, 2H), 7.87 (d, J = 8 .6 Hz, 2H); 1 3C NMR (63 MHz, CDCh) 8 92.2, 1 02.2, 1 17.0 (q, J = 283.4 Hz), 128.8, 132.3, 138.4, 177.5 (q, J = 36.2 Hz), 1 85. 1 .  Anal. Calcd for C10H�3IO2: C, 35. 1 1 ; H, 1.77; I, 37. 1 0. Found: C, 35. 19; H, 1 .74; I, 36.90. 
§ 8.2.5.2 Synthesis of 4,4,4-trifluoro-1-( 4-bromo-phenyl)-butane-1,3-dione, 33. To a solution of methyl trifluoroacetate (4.23 g, 33.0 mmol) in 50 mL of MTBE was added 25% NaOMe in MeOH (8.82 mL, 39.0 mmol). A solution of 4-bromoacetophenone (5 .97 g, 30.0 mmol) in 40 mL of MTBE was added to the mixture dropwise. After stirring for 48 h at room temperature, aqueous 3 N HCI 1 29 
(14.0 mL) was added. The organic layer was extracted with ether, washed with water and then brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo to yield the crude product which was recrystallized from isooctane to afford 6.17 g (70.0%) of product 33: mp 40 °C; 1H NMR (250 MHz, CDCh) o 6.53 (s, lH), 7.65 (d, J =  8.6 Hz, 2H); 7.81 (d, J =  8.6 Hz, 2H); 1 3C NMR (63 MHz, CDCh) o 92.3, 121.6 (q, J = 283.4 Hz), 129.0, 129.3, 131.8, 132.4, 177.4 (q, J = 36.3 Hz), 185.1. Anal. Calcd for C 10HJ3rF3O2: C, 40.71; H, 2.05 ; Br, 27.08. Found: C, 40.78; H, 1.98; Br, 27.09. 
§ 8.2.5.3 Synthesis of 4,4,4-trifluoro-l-(2-iodo-phenyl)-butane-1,3-dione, 36. To a solution of methyl trifluoroacetate (1.20 g, 8.9 mmol) in 20 mL of MTBE was added 25% NaOMe in MeOH (2.40 mL, 10.6 mmol). A solution of 2-iodoacetophenone (2.0 g, 8.1 mmol) in 40 mL of MTBE was added to the reaction mixture dropwise. After stirring for 48 h at room temperature, aqueous 3 N HCI (6 mL) of was added. The organic layer was extracted with ether, washed with water and then brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo to give 2.05 g (73.6%) of product 36: 1H NMR (250 MHz, CDCh) o 6.39 {s, lH), 7.17 {m, lH), 7.45 (m, 2H), 7.97 (d, 1 =  7.8 Hz, lH): 1 3C NMR (63 MHz, CDCh) o 92.8, 97.5, 117.1 (q, J = 282.7 Hz), 127.9, 128.3, 129.6, 132.8, 139.3, 141.1, 174.6 (q, J = 36.7 Hz), 190.53. Anal. Calcd for C10H�3IO2: C, 35.11; H, 1.77; I, 37. 10. Found: C, 35 .48; H, 1.77; I, 36.70. 130 
§ 8.2.5.4 Synthesis of 4,4,4-trifluoro-1-(3-iodo-4-methoxy-phenyl)-butane-1,3-
dione, 41. To a solution of methyl trifluoroacetate ( 1.55 g, 11.9 mmol) in 30 mL of MTBE was added 25% NaOMe in MeOH (3.23 mL, 14.1 mmol). A solution of 39 (3 .00 g, 10.9 mmol) in 90 mL of MTBE was added to the mixture dropwise via an addition funnel. After stirring for 72 h at room temperature, aqueous 3 N HCl (6 mL) was added. The organic layer was extracted with ether, washed with water and then brine, dried over anhydrous MgSO4, filtered, and concentrated using a rotary evaporator to give 3.52 g (86.9%) of 41 as a pale brown solid: 1H NMR (250 MHz, CDCh) o 3 .97 (s, 3H), 6.47 (s, IH), 6.88 (d, J = 8.7 Hz, IH), 7.94 (d, J = 7.8 Hz, lH) ,  8.35 (s, lH); 1 3C NMR (63 MHz, CDCh) o 56.7, 86.4, 91.8, 110.4, 117.2 (q , J = 282.9 Hz), 127.1, 129.9, 1 39.2, 162.7, 174.7 (q, J = 36.3 Hz), 184.7. Exact mass calcd for C1 1HsF3IO3 m/z 371.9470; found m/z 371.9467. 
§ 8.2.5.5 Synthesis of 4,4,4-trifluoro-l-(3-iodo-4-methyl-phenyl)-butane-l ,3-
dione, 48. To a solution of methyl trifluoroacetate (0.415 g, 3.2 mmol) in MTBE (5 mL) was added 25% NaOMe in MeOH (0.87 mL, 3 .8 mmol) .  A solution of 45 (0.765 g, 2.9 mmol) in 10 mL of MTBE was added to the mixture dropwise. After stirring for 39 h at room temperature, aqueous 3 N HC1 (1.5 mL) was added. The organic layer was extracted with ether, washed with water and then brine, dried over anhydrous MgSO4, fil tered, and concentrated using a rotary evaporator to give 0.862 g (82.3%) 131 
of 48 as a reddish brown liquid: 1H NMR (250 MHz, CDCh) o 2.49 (s, 3H), 6.49 (s, lH), 7.33 (d, J = 7.4 Hz, lH), 7.77 (d, J = 7.9 Hz, lH), 8.33 (s, lH); 1 3C NMR (63 MHz, CDCh) o 28.5, 92.2, 101.3, 117.1 (q, J = 283. l Hz), 127.2, 130.0, 132.0, 137.9, 148.3, 176.9 (q, J = 36.8 Hz), 184.5. Exact mass calcd for C1 1flsF3I02 m/z 355.9521; found m/z 355.9528. 
§ 8.2.6 Synthesis of Halogenated Benzenesulfonamides 31, 34, 37, 42, and 49 via 
Condensation of 1,3-diketones with 1 1. 1 34 
§ 8.2.6.1 Synthesis of 4-[5-(4-iodo-phenyl)-3-trifluoromethyl-pyrazol-1-yl]­
benzenesulfonamide, 31. To a stirred solution of diketone 29 (4.10 g, 12.0 mmol) in 120 mL of ethanol was added 4-(sulfamoylphenyl)hydrazine hydrochloride (2.95 g, 13.2 mmol). The mixture was refluxed for 24 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with water and then brine, dried over anhydrous MgS04, filtered, and concentrated in vacuo to give a pale brown solid. The crude product was purified by column chromatography (30% ethyl acetate in hexane) to give 5 .39 g (91.1 %) of 31 as a white solid. mp 180 °C: 1H NMR (250 MHz, CDCh) o 5 .04 (s, 2H), 6.78 (s, lH), 6.97 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.7 Hz, 2H), 7.73 (d, J = 8.4 Hz, 2H), 7.93 (d, J = 8.1 Hz, 2H); 1 3C NMR (63 MHz, CDCh) o 95.9, 106.7, 116.6 (q, J = 270.3 Hz), 125.6, 127.6, 128.0, 130.3, 138.3, 141 .8, 142.1, 144.0, 144.9 (q, J = 38.4 Hz). 132 
Anal. Calcd for C1�1 1F3IN3O2S: C, 38.96; H, 2.25; N, 8.52; I, 25.73 . Found: C, 38.98 ; H, 2.26; N, 8.42; I, 25 .49. 
§ 8.2.6.2 Synthesis of 4-(5-( 4-bromo-phenyl)-3-trijluoromethyl-pyrazol-1-yl]­
benzenesulfonamide, 34. To a stirred solution of diketone 33 (5.29 g, 1 8 .0 mmol) in 1 80 rnL of ethanol was added 4-(sulfamoylpheny])hydrazine hydrochloride (4.43 g, 19.8 mmol). The mixture was refluxed for 24 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with water and then brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo to give solid. The crude product was purified by column chromatography (30% ethyl acetate in hexane) to give 5.24 g (65.2%) of 31 as a white solid. 1H NMR (250 MHz, CDCh) 8 5.03 (s, 2H), 6.78 (s, lH), 7. 12  (d, J = 8.3 Hz, 2H), 7.46 (d, J = 8 .5 Hz, 2H), 7.53 (d, J = 8.3 Hz, 2H), 7.93 (d, J = 8.5 Hz, 2H); 1 3C NMR (63 MHz, CDCh) 8 106.7, 120.8 (q, J = 269.6 Hz), 124. 1, 125 .5, 127.4, 127.6, 130.3, 132.3, 141 .8, 142.0, 144. 1 (q, J = 38.7 Hz), 144.0. Anal . Calcd for C16H1 1  BrF3N3O2S: C, 43 .06; H, 2.48; N, 9.42; Br, 17.9 1. Found: C, 42.97; H, 2.56; N, 9. 15 ;  Br, 17.71 . 
§ 8.2.6.3 Synthesis of 4-(5-(2-iodo-phenyl)-3-trifluoromethyl-pyrazol-1-yl]­
benzenesulfonamide, 37. To a stirred solution of diketone 36 (0.598 g, 1 . 8 mmol) in 30 mL of ethanol was added 4-(sulfamoylphenyl)hydrazine hydrochloride (0.430 g, 1 .9 mmol). The 133 
mixture was refluxed for 26 h. After cooling to room temperature, the reaction 
mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate, 
washed with water and then brine, dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. The crude product was purified by column chromatography 
(35% ethyl acetate in hexane) to give 0.535 g (62%) of 37: mp 1 17 °C; 1H NMR (250 
MHz, CDCh) o 5.25 (s, 2H), 6 .75 (s, lH), 7. 1 5  (m, J = 7.4 Hz, lH), 7.30 (m, lH), 
7.40 (d, J = 8.2 Hz, 2H), 7.42 (s, lH), 7.8 1  (d, J = 8.5 Hz, 2H), 7.89 (d, J = 1.9 Hz, 
lH); 1 3C NMR (63 MHz, CDCh) o 99.4, 107.9, 1 16.6 (q, J = 269.6 Hz), 123.0, 
124.5, 1 27.3, 128.6, 13 1 .5, 134.4, 1 39.9, 141 .2, 142.2, 143 .7 (q, J = 38.4 Hz), 146. 1 .  
Anal . Calcd for C1Jl1 1FJIN3O2S : C ,  38.96; H, 2.25 ;  N, 8 .52; I, 25 .73. Found: C, 
39.04; H, 2.33; N, 8.37; I, 25.49. 
§ 8.2.6.4 Synthesis of 4-(5-(3-iodo-4-methoxy-phenyl)-3-trifluoromethyl-pyrazol-
1-yl]-benzenesulfonamide, 42. 
To a stirred solution of diketone 41 (0.744 g, 2.0 mmol) in 35 mL of ethanol 
was added 4-(sulfamoylphenyl)hydrazine hydrochloride (0.507 g, 2.2 mmol). The 
mixture was refluxed for 24 h. After cooling to room temperature, the reaction 
mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate, 
washed with water and then brine, dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. The crude product was purified by column chromatography 
(40% ethyl acetate in hexane) to give 0.605 g (57.8%) of 42 as a white solid: mp 
1 86 °C; 1H NMR (250 lVIHz, DMSO-d6) o 3 .82 (s, 3H), 6.99 {d, J = 8.6 Hz, lH), 7. 19 
134 
(m, 2H), 7.54 (s, 2H), 7.58 (d, J = 8.7 Hz, 2H), 7.83 (d, J = 2.0 Hz, lH), 7.91 (d, J = 8.5 Hz, 2H); 13C NMR (63 MHz, DMSO-d6) o 56.6, 86.5, 106.3, 111.3, 121.3 (q, J = 269.2 Hz), 122.3, 126.0, 126.8, 130.4, 139.2, 141.0, 142.7 (q, J = 31.6 Hz), 143.5, 144.1, 158.5 . Anal. Calcd for CnH13F3IN3O3S: C, 39.02; H, 2.50; N, 8.03 ; I, 24.25 . Found: C, 39.34; H, 2.57; N, 7.94; I, 23.90. · 
§ 8.2. 6.5 Synthesis of 4-[5-(3-iodo-4-methyl-phenyl)-3-trijluoromethyl-pyrazol-1-
yl]-benzenesulfonamide, 49. To a stirred solution of diketone 48 (0.70 g, 1.9 mmol) in 30 mL of ethanol was added 4-(sulfamoylphenyl)hydrazine hydrochloride (0.50 g, 2.2 mmol). The mixture was refluxed for 24 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with water and then brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo to yield a yellow solid. The crude product was purified by column chromatography (30% ethyl acetate in hexane) to give 0.509 g (51.0%) of 49 as a white solid: mp 177 °C; 1H NMR (250 MHz, DMSO-d6) o 2.35 (s, 3H), 7.11 (d, 
J = 1.4 Hz, lH), 7.28 (m, 2H), 7. 56 {m, 4H), 7.90 (m, J = 1 .6 Hz, 3H); 1 3C NMR (63 MHz, DMSO-d6) o 27.3, 1 0 1 .5, 1 06.6, 121.2 (q, J = 269.5 Hz), 126. l ,  126.6, 127.5, 128.7, 129.8, 138.5, 140.9, 142.2 (q, J = 38. 1 Hz), 142.3, 143.3, 1 44.2. Anal. Calcd for C 17H1 3F3IN3O2S: C, 40.25; H, 2.58; N, 8.28; I, 25 .02. Found: C, 40.55; H, 2.73 ; N, 8.07; I, 24.76. 135 
§ 8.2.7 Synthesis of Target Compounds A and B via Coupling of 31 and 37 with 
Di boron Ester 23. 224-227 
§ 8.2.7.1 Synthesis of 4-[5-(4-(5,5-dimethyl-[1,3,2}dioxaborinan-2-yl)-phenyl}-3-
trijluoromethyl-pyrawl-l-yl}-benzenesulfonamide, A. 
Into a dried, three-necked round-bottomed flask was added PdCh( dppf) 
(0. 1 1 5 g, 0. 16 mmol), KOAc ( 1 .54 g, 1 5 .7 mmol), and 
bis(neopentylglycolato)diboron 23 ( 1 .30 g, 5 .7 mmol) in a glove bag. The flask was 
flushed with nitrogen and then charged with 20 mL of DMSO. After stirring for 15  
min, aryl iodide 31 (2.58 g ,  5 . 2  mmol) dissolved in  16 mL of DMSO was added to 
the reaction mixture. The flask was fitted with a reflux condenser and heated at 80 °C 
for 20 h. The reaction mixture was then cooled to room temperature, extracted with 
ethyl acetate, washed with water, dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo to give a copper colored solid. The product was purified by 
column chromatography over silica gel (45% ethyl acetate in hexane) to give 1 .6 1  g 
(64. 1 %) of the target compound A as a crystalline white solid: 1H NMR (400 MHz, 
CDCh) o 1 .0 1  (s, 6H), 3 .75 (s, 4H), 5 .46 (s, lH), 7. 19 (d, J = 7.8 Hz, 2H), 7.42 (d, J 
= 8 .5 Hz 2H), 7 .76 (d, J = 1 .8 Hz, 2H), 7 .85 (d, J = 8.6 Hz, 2H); 1 3C NMR (63 MHz, 
CDCh) o 2 1 .8, 3 1 .9, 72.4, 106.6, 12 1 .0 (q, J = 269.6 Hz), 125.5, 127.5, 1 27.9, 130.4, 
134.4, 14 1 .5, 142.4, 144. 1 (q, J = 38.6 Hz), 145.3;  1 1 B NMR ( 128 MHz, CDCh) 8 
27.7. Anal. Calcd for C21H21BF3N3O4S :  C, 52.63 ; H, 4.42; N, 8 .77. Found: C, 52.9 1 ;  
1 36 
H, 4.62; N, 8.53 ; Exact mass calcd for C21H21BF3N3O4S mlz 479. 130; found mlz 479. 13 1 .  
§ 8.2.7.2 Synthesis of 4-[5-(2-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-phenyl]-3-
trijluoromethyl-pyrazol-1-yl J-benzenesulfonamide, B. Into a dried, three-necked round-bottomed flask was added PdCh( dppf) (0.098 g, 0. 13 mmol), KOAc (1 .3 1  g, 13 .5 mmo]), and bis(neopentylglycolato)diboron 23 ( 1 . 1 1  g, 4.9 mmol) in a glove bag. The flask was flushed with nitrogen and then charged with 20 mL of DMSO. After stirring for 15  min, aryl iodide 37 (2.20 g ,  4.5 mmol) dissolved i n  10 mL DMSO was added to the reaction mixture. The flask was fitted with a reflux condenser and heated at 80 °C for 24 h. The reaction mixture was then cooled to room temperature, product extracted with ethyl acetate, washed with water, dried over anhydrous MgSO4, filtered, and concentrated in vacuo to yield a solid. The crude product was purified via column chromatography (40% ethyl acetate in hexane) to give 1 . 10g (5 1 .6%) of the product: 
1H NMR (250 MHz, acetone-d6) 6 0.83 (s, 6H), 3 .5 1 (s, 4H), 6.67 (s, 2H), 6.79 (s, lH), 7.47 (m, 5H), 7. 85 (m, 3H); 1 3C NMR (63 MHz, acetone-�) 6 21 .9, 32 . 1 ,  72.7, 107.4, 120.6 (q, J = 289.6 Hz), 125 .4, 127.6, 129.6, 13 1 .3, 1 3 1 .3 ,  135 . 1 ,  135.7, 143.0, 143 .4, (q, J = 36.6 Hz), 144.1 ,  147.7; 1 1 B NMR (128 MHz, acetone-d6) 6 26.7. Exact mass calcd for C21H2 1BF3N3O4S m/z 479. 1302; found mlz 479.13 13. 137 
§ 8.3 EXPERIMENTAL PROCEDURES FOR UNNATURAL CYCLIC 
AMINO ACIDS E AND F. 
§ 8.3.1 Synthesis of 1,4-diboration Products 52 and 54 
§ 8.3.1.1 Synthesis of 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)­
cyclopentanone, 52. 264 A dry three-necked round-bottomed flask flushed with nitrogen was charged with CuCl (0.980 g, 9.9 mmol) in a glove bag. DMF (54 mL) was added to the flask and the mixture stirred for 1 h. KOAc (0.972 g, 9.9 mmol) was then added fol1owed by bis(pinacolato)diboron, 50 (2.51 g, 9.9 mmol). After stirring for 20 min, cyclopentenone 51 (0.77 mL, 9.0 mmol) was added to the reaction mixture dropwise. The resu]ting solution was stirred at room temperature for 24 h, and then quenched with 20 mL of water. The mixture was extracted with benzene, the combined organic layers were washed with water, dried over anhydrous MgSO4, and solvent removed under reduced pressure on a rotary evaporator to yield a pale yellow liquid. The crude product was purified by column chromatography (30% ethyl acetate in hexane) to give 1 .52 g (24. 1 % ) of the product 52 as a colorless liquid: 1H NMR (250 MHz, CDCb) o 1 .25 (s, 12H), 1 .67 (m, lH), 1 .85 (m, lH), 2.02-2.35 (m, 7H); 1 3C NMR (63 MHz, CDCh) o 24.6, 25. 1 ,  38.7, 40.0, 83 .3, 220.7; 1 1B NMR (128 MHz, CDCb) 
o 34.7. Exact mass calcd for C1 1H19BO3 m/z 210. 1429; found mlz 210.1434. 138 
§ 8.3.1.2 Synthesis of 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)­
cycloheptanone, 55. 264 A dry three-necked round-bottomed flask flushed with nitrogen was charged with CuCl (2.47 g, 25.0 mmol) in a glove bag. DMF (180 mL) was added to the flask and the mixture stirred for 1 h. KOAc (2.45 g, 25.0 mmo]) was then added followed by bis(pinacolato)diboron, 50 (6.34 g, 25.0 mmol). After stining for 20 min, cycloheptenone 54 (2.50 g, 22. 7 mmo]) was added to the reaction dropwise. The reaction mixture was stirred at room temperature for 24 h, and then quenched with water. The mixture was extracted with benzene, the combined organic layers were washed with water, dried over anhydrous MgSO4, and solvent removed under reduced pressure on a rotary evaporator to yield a white solid. The crude product was purified by column chromatography (10% ethyl acetate in hexane) to give 2.02 g (37.4%) of the product 55 as a white crystalline solid. 1H NMR (250 MHz, CDCh) o 1.23 (s, 12H), 1.49 {m, 2H), 1.55-1.63 {m, lH), 1.78-1.96 (m, 4H), 2.51 (m, 4H); 1 3C NMR (63 MHz, CDCh) ii 24.2, 24.6, 30.9, 31.9, 43 .6, 44.7, 83 .2, 215.1; 1 1B NMR (128 MHz, CDCh) ii 34.7. Exact mass calcd for C 1 3H23BO3 m/z 238.1743 ; found m/z 238.1739. 139 
§ 8.3.2 Synthesis of Boronated Hydantoins 53 and 56 
§ 8.3.2.1 Synthesis of 7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,3-diaza­
spiro[ 4.4 ]nonane-2,4-dione, 53. 259 An Ace pressure tube was charged with a mixture of 52 (0.420 g, 2 mmol), (N}4)2CO3 (0.961 g, 10.0 mmol}, and KCN (0.470 g, 7.0 mmol) in 10 mL of ethanol and 10 mL of water. The reaction vessel was sealed and heated to 65 °C in an oil bath for 18 h. The reaction was then coo,ed to room temperature and opened carefully in a hood. The solvent was removed under reduced pressure using a rotary evaporator. The resultant white solid was taken up into ethyl acetate and washed with water and then brine. The organic layer was dried over anhydrous MgSO4• filtered, and concentrated under reduced pressure to yield a white solid. The crude product was purified by column chromatography over silica gel using ethyl acetate as eluent to yield 0.318 g (56.7%) of 53: 1H NMR (250 MHz, DMSO-d6) major diastereomer o 1.16 (s, 12H), 1.40-2.10 (m, 7H), 8.16 (br s, lH), 10.50 (br s, l H); 
13C NMR (63 MHz, DMSO) o 24.5, 27.0, 37.8, 40.0, 69.3, 82.9, 156.3, 178. 8 ;  1 1B NMR (128 MHz, DMSO-d6) o 35.7. Exact mass calcd for C13H21BN204 m/z 280.1597; found m/z 280.1599. 
§ 8.3.2.2 Synthesis of 7-( 4,4,5,5-tetramethyl-[1,3,2 ]dioxaborolan-2-yl)-1,3-diaza­
spiro[ 4. 6 ]undecane-2,4-dione, 56 An Ace pressure tube was charged with a mixture of 54 (0.714 g, 3 mmol), of (�)2CO3 (1.44 g, 15.0 mmol), and KCN (0.705 g, 10.5 mmol) in 10 mL of ethanol 140 
and 10 mL of water. The reaction vessel was sealed and heated to 65 °C in an oil bath for 18 h. The reaction was then cooled to room temperature and opened carefully in a hood. The solvent was removed under reduced pressure using a rotary evaporator. The resultant white solid was taken up into ethyl acetate and washed with water and then- brine. The organic layer was dried over anhydrous- MgSO4; and concentrated under reduced pressure to yield a white solid. The crude product was purified by column chromatography (80% ethyl acetate in hexane) to yield 0.46 g (50%) of 56: 1H NMR (400 MHz, DMSO-d6) major diastereomer o 1.06 (s, lH), 1.16 (s, 12H), 1 .56-1.90 (m, lOH), 8.24 (br s, lH), 10.47 (br s, lH); 1 3C NMR (100 MHz, DMSO-d6) o 21.8, 24.8, 28.6, 29.3, 36.4, 38 .4, 65.4, 82.9, 156.3, 179.4; Exact mass calcd for C1sH2sBN2O4 mlz 308.190; found mlz 308.1915. 
§ 8.3.3 Synthesis of Boronated Amino Acids E and F 
§ 8.3.3.1 Synthesis of 1-amino-3-boronocyclopentanecarboxylic acid, E An Ace pressure tube was charged with hydantoin 53 (0. 140 g, 0.5 mmol) and concentrated HCl (5 mL). The tube was sealed and heated to 150 °C in an oil bath for 24 h. The resulting mixture was cooled to room temperature and opened careful ly in a hood. TLC indicated disappearance of starting material . The reaction mixture was treated with charcoal and filtered through Celite. The Celite pad was washed repeatedly with water. The filtrate, and the washes were combined and the water removed to yield a diastereomeric mixture of E as the solid hydrochloride. The solid turns brown at 256 °C without melting. Rr = 0.71 (isopropanol:water:acetic 
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acid, 1 .0: 1 .0:0.5): 1H NMR (250 MHz, D2O) major diastereomer 8 1 .50-2.50 (m); 
1 3C NMR (63 MHz, D2O) 8 28.0, 37.2, 38.8, 65.7, 175.2; 1 1B NMR (128 MHz, D2O) 
8 28.8. Exact mass calcd for C9H 1sBNO5 (M+H-Cl+gly-2H2O, obtained in a glycerol 
matrix) m/z 230. 1 20; found mlz 230. 137. § 8.3.3.2 Synthesis of 1-amino-3-boronocycloheptanecarboxylic acid, F 
An Ace pressure tube was charged with hydantoin 56 (0. 1 54 g, 0.5 mmol) 
and concentrated HCI (5 mL). The tube was sealed and heated to 150 °C in an oil 
bath for 24 h. The resulting mixture was cooled to room temperature and opened 
carefully in a hood. TLC indicated disappearance of starting material . The reaction 
mixture was treated with charcoal and filtered through Celite. The Celite pad was 
washed repeatedly with water. The filtrate, and the washes were combined and the 
water removed under reduced pressure to yield a diastereomeric mixture of F as the 
solid hydrochloride. The solid turns brown at 248 °C without melting. Rr= 0.65 
(isopropanol :water:acetic acid, 1 .0: 1 .0 :0.5): 1H NMR (400 MHz, D2O) major 
diastereomer 8 1 . 16- 1 .20 (m), 1 .30- 1 .50 (m), 1 .70- 1 .90 (m), 2.07-2.3 1  (m); 1 3C NMR 
( 100 MHz, D20) 8 24.7, 32.9, 33 .6, 38 . 1 ,  38.5 ,  66.2, 177.5 ; 1 1B NMR ( 128 MHz, 
D2O) 8 3 1 .7. Exact mass calcd for C 1 1H22BNOs (M+H-Cl+gly-2H2O, obtained in a 
glycerol matrix) mlz 258. 1 5 1 ;  found m/z 258. 150. 
142 
§ 8.4 SYNTHESIS OF INTERMEDIATES 64 AND 69 FOR PREPARATION OF COMPOUND G 
§ 8.4.1 Synthesis of Polyol Tosylate, 64. 200 § 8.4.1.1 Synthesis of 1,3-bis-benzyloxy-propan-2-ol, 59. A three-necked 500-mL round-bottomed flask equipped with a mechanical stirrer, a reflux condenser, and an addition funnel was charged with KOH (84.0 g, 1 .5 mol) and 10 mL of water. After stirring for 20 min, benzyl alcohol (208 mL, 2 mol) was added to the mixture. After stirring for 10  min, tetra-n-butylammonium bromide (32.2 g, 0. 10 mol) and sodium iodide (1 5.0 g, 0. 10 mol) was added. The reaction mixture turned yellow. After stirring for 40 min, epichlorohydrin (39.2 mL, 0.5 mol) was added dropwise to the reaction mixture with vigorous stirring. The resulting solution was heated to 70 °C for 72 h. After cooling to room temperature, the· reaction mixture was diluted with aqueous 3 N HCl ( lOOmL), extracted with ether, washed with water and then brine, dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure on a rotary evaporator. The residue was purified by Kugelrohr distillation: first fraction (60 °C-120 °C) excess benzyl alcohol ; second fraction ( 160 °C-210  °C) product: to yield 148.92 g (54.8%) of 59 as a pale yellow oil .  1H NMR (250 MHz, CDCh) o 2.90 (br s, lH}, 3 .50 (m, 4H), 3 .98 (m, lH}, 4.49 (s, 4H}, 7 .29 (s, lOH); 1 3C NMR (63 MHz, CDCh) o 69.3, 70.0, 73.2, 127 .5, 128.05, 1 28 .2, 1 37.8. 143 
§ 8.4.1.2 Synthesis of 1,3-bis-(2-benzyloxy-1-benzyloxymethyl-ethoxy)-propan-2-
ol, 60. 
A three-necked 500-mL round-bottomed flask equipped with a mechanical 
stirrer, a reflux condenser, and an addition funnel was charged with KOH ( 14.3 g, 
0.26 mol) iil 7 mL of water. After stirring for 20 min, 59 (91 .8 g, 0.34 mol) was 
added to the mixture. After stirring for 10 min, tetra-n-butylammonium bromide 
(5.48 g, 0.02 mol) and sodium iodide (2.55 g, 0.02 mol) were added. The reaction 
mixture turned yellow. After stirring for 40 min, epichlorohydrin (6.66 mL, 0.09 
mol) was added dropwise to the reaction mixture with vigorous stirring. The 
resulting solution was heated to 70 °C for 72 h. After cooling to room temperature, 
the reaction mixture was diluted with aqueous 3 N HCl ( 40 mL), extracted with 
ether, washed with water and then brine, dried over anhydrous MgSO4, filtered, and 
concentrated under reduced pressure on a rotary evaporator. The residue was purified 
by Kugelrohr distillation to yield 66.2 g (64.5%) of 60 as a pale yellow oil .  1H NMR 
(250 MHz, CDCh) 6 2.89 (s, IH), 3.48 (m, 9H), 3 .62 (m, SH), 3 .90 (m, SH), 4.47 (s, 
8H), 7 .23 (s, 20H); 13C NMR (63 MHz, CDCh) 6 69.2, 69 .9, 71 .1 , 71 .6, 73.1 , 78.5, 
127 .4, 128.1 , 137.8. 
§ 8.4.1.3 Synthesis of 3-[2-(2-benzyloxy-1-benzyloxymethyl-ethoxy )-1-(2-
benzyloxy-1-benzyloxymethyl-ethoxy-methyl)ethoxy )]propene, 62. 
Sodium hydride (10.3 g, 430.7 mmol) was added to a solution of alcohol 60 
(64.6 g, 107.7 mmol) in 265 mL of DMF added at O °C. After stirring for 30 min, 
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ally bromide (46.6 mL, 538.4 mmol) was added to the reaction mixture dropwise. After completion of addition, the reaction mixture was stirred in an ice-bath for 60 min and then stirred at room temperature for 18 h .The reaction mixture was then carefully treated with water (40 mL) to remove unreacted sodium hydride, diluted with ether; washed successively with water and brine, dried over anhydrous MgS04, and filtered. The solvent was removed under reduced pressure to give a yellow oil which was purified by column chromatography over silica gel (20% ethyl acetate in hexane) to yield 52.8 g (76.5%) of product 62: 1 H NMR (250 MHz, CDCh) b 1.22 (t, 
J = 1.0 Hz, 2H), 2.00 (s, 2H), 3.50-3.80 (m, 15H), 4.10 (m, 3H), 4.49 (s, 8H), 5.09 (dd, J =  10.5, 1 .7 Hz, IH), 5.22 (dd, J =  17.2, 1.5 Hz, IH), 5.90 (m, lH), 7.28 (s, 20H); 13C NMR (63 MHz, CDCh) b 69.9, 70.2, 71 .0, 73.1, 77.5 ,  78.5 , 116.3, 1 27.4, 128.1, 135.2, 138.2. § 8.4.1.4 Synthesis of 3-(2-(2-benzyloxy-1-benzyloxymethyl-ethoxy )-1-(2-benzyloxy-1-benzyloxymethyl-ethoxy-methyl)ethoxy )]propan-1-ol, 63. A three-necked round-bottomed flask was charged with BH3 ·THF (30.1 mL, 30.1 mmol) under nitrogen atmosphere. The solution was cooled to 0 °C in an ice­bath and cyclohexene (6. 10 mL, 60.1 mmol) was added via a syringe. After stirring for 2 h, alkene 62 (9.64 g, 15.0 mmol) THF ( 15  mL) was added to the flask and the resulting mixture was stirred under nitrogen atmosphere for 15h at room temperature. The reaction mixture was then cooled to 0 °C in an ice-bath and the organoborane was oxidized using a mixture of sodium perborate tetrahydrate (13.9 g, 145 
90.2 mmol) and water (10 mL). The reaction mixture was allowed to come to room temperature and concentrated in vacuo. The residue was extracted with ether, washed with water and then brine, dried over anhydrous MgSO4, filtered and concentrated in 
vacuo to obtain a pale yellow oil. The product was purified by column chromatography over silica gel (50% ethyl acetate in hexane) to obtain 7 .34 g (75%) of 63 as a colorless liquid: 1H NMR (250 MHz, CDCh) <> 1.78 (m, 2H), 3.30 (br s, lH), 3.54 (m, 9H), 3.75 (m, IOH), 4.51 (s, SH), 7.30 (s, 20H); 13C NMR (63 MHz, CDCh) S 32.0, 61.2, 69.2, 69.9, 73 .3, 78.1, 127.5, 128.2, 137.9. 
§ 8.4.1.5 Synthesis of toluene-4-sulf onic acid-3-(2-(2-benzyloxy-1-
benzyloxymethyl-ethoxy )-1-(2-benzyloxy-1-benzyloxymethyl-ethoxy­
methyl)ethoxy )]propyl ester, 64. A dry, three-necked round-bottomed flask was charged with polyol 63 (0.855 g, 1.30 mmol) and pyridine (2.85 mL, 35.1 mmol). The solution was cooled to -5 °C in an ice-bath. p-toluenesulfonyl chloride (0.372 g, 1.9 mmol) was added to the reaction mixture and the solution was stirred for 6 h while maintaining the bath temperature at -5 °C. The reaction mixture was then poured into a mixture of ether (80 mL), ice (10 g), and concentrated HCl (3 mL). The ether layer was separated, washed with cold water, dried over anhydrous MgSO4, filtered, and concentrated in 
vacuo to yield 0.898 g (84.9%) of tosylate 64. 1H NMR (250 MHz, CDCh) S 1.89 (m, 2H), 2.38 (s, 3H), 3.48-3 .80 (m, 17H), 4.13 (m, 4H), 4.50 (s, SH), 7.28 (s, 22H), 146 
7.75 (d, J = 8 .2 Hz, 2H); 13C NMR (63 MHz, CDCh) <> 2 1 .5 ,  29.5, 65.6, 67 .7, 69.7, 
70.0, 73.2, 78.5, 127.5, 127.7, 128.2, 129.7, 1 33.0, 138 . 1 ,  144.5 .  
§ 8.4.2 Synthesis of Mesylate 69.259 
§ 8.4.2.1 Synthesis of 2-(3-oxo-cyclopentyl)-malonic acid diethyl ester, 65. 283 
A dry three-necked round-bottomed flask was charged with diethyl malonate 
(4.55 mL, 30 mmol) in anhydrous ethanol (2 1 mL) under nitrogen atmosphere. The 
solution was cooled to -5 °C and sodium ethoxide in ethanol (0. 1 mL, 0.28 mmol) 
was added to it. After stirring the reaction mixture for 30 min, 2-cyclopentene- 1 -one 
(2.57 mL, 30 mmol) in 20 mL of ethanol was added dropwise at -5 °C. After the 
addition was complete, the solution was allowed to wann to room temperature and 
stirred for 15  h. The reaction mixture was then treated with acetic acid (2 mL), 
concentrated in vacuo, extracted into ether, washed with water and then brine, dried 
over anhydrous MgSO4, filtered and concentrated in vacuo to give a pale yellow 
l iquid. The product was purified by column chromatography over silica gel (20% 
ethyl acetate in hexane) to yield 6 . 19 g (85 .2%) of 65 as a colorless liquid: 1H NMR 
(250 MHz, CDCh) <> 1 .27 (t, J = 7. 1 Hz, 3H), 1 .29 {t, J = 7. 1 Hz, 3H), 1 .67 (m, IH), 
2.03 (dd, J = 1 8 .4, 1 1 .0 Hz, lH), 2.5 1 (dd, J = 18 .3, 7.2 Hz, IH), 2.20-2 .36 (m, 3H), 
2.84 (m, lH), 3 .35 (d, J = 9.4 Hz, IH), 4.22 (m, 4H); 1 3C NMR (63 MHz, CDCh) <> 
13 .9, 27 .3, 36. l ,  38 .0, 42.7, 56.3, 6 1 .4, 167.9, 168.0, 2 16.9. 
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§ 8.4.2.2 Synthesis of 2-(1,4-dioxa-spiro[4.4]non-7-yl)-ma/,onic acid diethyl ester, 
66.283 
To a solution of 65 (2.33 g, 9.6 mmol) in 1 50 mL of benzene contained in a 
round-bottomed flask was added ethylene glycol ( 1 .07 mL, 19 .2 mmol), and p­
toluenesulfonic acid (0.037 g, 0. 19  mmol). The flask was fitted with a Dean Stark 
apparatus and a reflux. condenser. After being refluxed at 1 10 °C for 27 h, the 
mixture was cooled to room temperature and treated with aqueous 3 N NaOH. The 
organic benzene layer was washed with water and then brine, dried over anhydrous 
MgSO4, filtered and concentrated in vacuo to give a yellow liquid which was 
purified by column chromatography over silica gel ( 1 5% ethyl acetate in hexane) to 
yield 2.26 g (82.2%) of 66 as a colorless liquid: 1H NMR (250 MHz, CDCb) o 1 .26 
(t, J = 7.3 Hz, 6H), 1 .44 (m, lH), 1 .59 (dd, J = 13 .5 ,  9.6 Hz, lH), 1 .75-2.00 (m, 3H), 
2 .09 (dd, f= 13 .6, 7.9 Hz, lH), 2 .67 (m, lH), 3 .27 (d, J = 10. 12  Hz, lH), 3 .85-3.92 
(m, 4H), 4. 1 8  (q, J = 1.0 Hz, 2H), 4. 19 (q, J = 1 . 1  Hz, 2H); 1 3C NMR (63 MHz, 
CDCh) 8 14.0, 28. 1 ,  35 .4, 36.6, 40.5, 57 .0, 6 1 . 1 ,  64. 1 ,  1 16.9, 168.4, 168.5 . 
§ 8.4.2.3 Synthesis of (l,4-dioxa-spiro[4.4]non-7-yl)-acetic acid ethyl ester, 67.283 
To a solution of KOH ( 1 .80 g, 27.9 mmol) in 45 mL of anhydrous ethano1 
was added diester 66 (7 .99 g, 27 .9 mmol) in 5 mL of anhydrous ethanol under a 
nitrogen atmosphere. After stirring for 6 h at room temperature, the reaction mixture 
was quenched by addition of di lute HC1 ( 1 .5 mL, 3 : 1 ,  HC1 :H2O). Ethanol was 
removed under reduced pressure, and the residue added to a mixture of 8 g of ice and 
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2 mL of concentrated HCI. The product was extracted immediately into CH2Cb, washed with brine, dried over anhydrous MgSO4 and concentrated in vacuo to yield a dark yellow liquid. This residue was heated at 160 °C for 6 h under reduced pressure to afford a reddish brown liquid which was which was purified by column chromatography over silica gel (10% ethyl acetate in hexane) to yield 4.0 g (66.9 %) of monoester 67: 1H NMR (250 MHz, CDCh) o 1.25 (t, J =  7.1 Hz, 3H), 1.34 (m, lH), 1.50 (dd, J = 13.4, 8.4 Hz, lH), 1.79-1.96 (m, 3H), 2.09 (dd, J = 13.4, 7.2 Hz, lH), 2.33-2.36 (m, 3H), 3.86-3.92 (m, 4H), 4.10 (q, J = 7.1 Hz, 2H); 1 3C NMR (63 MHz, CDCh) o 14.1, 30.0, 33 .9, 35.8, 40.2, 42.3, 60.1, 64.1, 64.1, 117.5, 172.6. 
§ 8.4.2.4 Synthesis of 2-(1,4-dioxa-spiro[4.4]non-7-yl)-ethanol, 68. To a suspension of LiAI� (0.320 g, 7.9 mmol) in THF (20 mL) at -5 °C was added ester 67 (1.14 g, 5 .3 mmol) via syringe dropwise under nitrogen. The mixture was stirred for 40 min at -5 °C and then heated to reflux for 4 h. The reaction mixture was then cooled to -5 °C and hydrolyzed with water. The mixture was stirred for an additional 30 min at room temperature. The resulting white solid was filtered and the filtrate poured into a mixture of ether and water. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure to give a pale yellow liquid which was chromatographed over si lica gel (50% ethyl acetate in hexane) to yield 0.329 g (35.9%) of a 68 as a colorless liquid: 1 H NMR (250 MHz, CDCh) o 1.44 (m, 2H), 1.66 (m, 2H), 1.86 (m, 3H), 2.04 (m, 2H), 2.26 (br s, lH), 149 
3.62 (t, J = 6.8 Hz, 2H), 3.89 (m, 4H); 1 3C NMR (63 MHz, CDCh) o 30.3, 34.3, 35.8, 38.6, 42.6, 61.4, 63.9, 64.1, 117.7. § 8.4.2.5 Synthesis of 2-(1,4-dioxa-spiro[4.4]non-7-yl)methanesulfonic acid ethyl ester, 69. To a solution of alcohol 68 (0.270 g, 1.6 mmol) in dry THF (4 mL) was added triethylamine (0.440 mL, 3.14 mL) and a solution of methanesulfonyl chloride (0.18 mL, 2.4 mmol) in THF (1 mL) at -5 °C under nitrogen. The yellow reaction mixture was allowed to warm to room temperature and stirred for 4 h. The reaction mixture was yellow in color. After stirring for 4 h, the mixture was treated with aqueous saturated solution of sodium bicarbonate (5 mL). The resulting solution was extracted into ether, washed with water and brine, dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure to afford product which was chromatographed over silica gel (40% ethyl acetate in hexane) to yield 0.250 g (63.6%) of 69: 1H NMR (250 MHz, CDCh) o 1.32-1.42 (m, 4H), 1 .77- 1 .88 (m, 4H), 2.00-2.02 (m, lH), 3.00 (s, 3H), 3.89 (m, 4H), 4.22 (t, J = 6.5 Hz, 2H), 3.89 (m, 4H); 1 3C NMR (63 MHz, CDCh) o 29.9, 33.8, 34.8, 35.7, 37.2, 42.3 ,  64.0, 64. 1 ,  68.7, 117.3 .  1 50 
§ 8.5 EXPERIMENT AL PROCEDURE FOR SYNTHESIS OF 
RADIOLABELED ANALOGUE OF CELECOXIB, H, VIA BORONA TE 
ESTER, A. 
§ 8.5.1 Synthesis of Boronate Ester, A. The synthesis of boronated precursor, A, was accomplished using the procedure outlined in Section 8.2. 7 . 1 . 
§ 8.5.2 Radiolabeling Procedure No-carrier-added Na1 23I (74 MBq in 0. 1 % aqueous NaOH) was placed into a 2 mL Wheaton vial containing boronate ester A ( 1 00 µL of 2.08 x 10-2 M solution in 50% aqueous THF). To this was added chloramine-T ( 100 µL of 5.0 1 x 10-2 M solution in 50% aqueous THF). The reaction vial was sealed and covered with aluminum foil. After stirring for 3 h at room temperature, a drop of sodium thiosulfate pentahydrate was added to decompose the excess iodine and the radiochemical product was isolated by passing it through a silica gel Sep-pak cartridge (eluted with petroleum ether-ethyl acetate, 2: 1 ). The radiochemical yield was determined by radio-TLC (aluminum backed silica gel plate; petroleum ether­ethyl acetate, 2: 1 ) , Rr = 0.44. The radiochemical yield was determined to be 56% and the decay corrected radiochemical purity was 99.55%. 15 1 
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